provider: cyberian
model: deep-research
cached: false
start_time: '2026-01-15T13:08:06.676302'
end_time: '2026-01-15T13:25:19.950373'
duration_seconds: 1033.27
template_file: templates/gene_research_go_focused.md
template_variables:
organism: human
gene_id: ACSL4
gene_symbol: ACSL4
uniprot_accession: O60488
protein_description: 'RecName: Full=Long-chain-fatty-acid--CoA ligase 4 {ECO:0000305};
EC=6.2.1.3 {ECO:0000269|PubMed:21242590, ECO:0000269|PubMed:22633490, ECO:0000269|PubMed:24269233};
AltName: Full=Arachidonate--CoA ligase {ECO:0000305}; EC=6.2.1.15 {ECO:0000269|PubMed:21242590};
AltName: Full=Long-chain acyl-CoA synthetase 4; Short=LACS 4;'
gene_info: Name=ACSL4; Synonyms=ACS4, FACL4, LACS4;
organism_full: Homo sapiens (Human).
protein_family: Belongs to the ATP-dependent AMP-binding enzyme family.
protein_domains: AMP-bd_C_sf. (IPR045851); AMP-binding_CS. (IPR020845); AMP-dep_synth/lig_dom.
(IPR000873); ANL_N_sf. (IPR042099); AMP-binding (PF00501)
provider_config:
timeout: 1800
max_retries: 3
parameters:
allowed_domains: []
agent_type: claude
port: 3284
skip_permissions: true
citation_count: 11

Question

Gene Research for Functional Annotation

⚠️ CRITICAL: Gene/Protein Identification Context

BEFORE YOU BEGIN RESEARCH: You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.

Target Gene/Protein Identity (from UniProt):

• UniProt Accession: O60488
• Protein Description: RecName: Full=Long-chain-fatty-acid--CoA ligase 4 {ECO:0000305}; EC=6.2.1.3 {ECO:0000269|PubMed:21242590, ECO:0000269|PubMed:22633490, ECO:0000269|PubMed:24269233}; AltName: Full=Arachidonate--CoA ligase {ECO:0000305}; EC=6.2.1.15 {ECO:0000269|PubMed:21242590}; AltName: Full=Long-chain acyl-CoA synthetase 4; Short=LACS 4;
• Gene Information: Name=ACSL4; Synonyms=ACS4, FACL4, LACS4;
• Organism (full): Homo sapiens (Human).
• Protein Family: Belongs to the ATP-dependent AMP-binding enzyme family.
• Key Domains: AMP-bd_C_sf. (IPR045851); AMP-binding_CS. (IPR020845); AMP-dep_synth/lig_dom. (IPR000873); ANL_N_sf. (IPR042099); AMP-binding (PF00501)

MANDATORY VERIFICATION STEPS:

1. Check if the gene symbol "ACSL4" matches the protein description above
2. Verify the organism is correct: Homo sapiens (Human).
3. Check if protein family/domains align with what you find in literature
4. If you find literature for a DIFFERENT gene with the same or similar symbol, STOP

If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:

DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE. Instead:
- State clearly: "The gene symbol 'ACSL4' is ambiguous or literature is limited for this specific protein"
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")
- Describe the protein based ONLY on the UniProt information provided above
- Suggest that the protein function can be inferred from domain/family information

Research Target:

Please provide a comprehensive research report on the gene ACSL4 (gene ID: ACSL4, UniProt: O60488) in human.

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

Output

ACSL4 (Long-chain-fatty-acid--CoA ligase 4): A Comprehensive Review

Introduction

Acyl-CoA Synthetase Long-Chain Family Member 4 (ACSL4), also known as FACL4, ACS4, or LACS4, is an X-linked gene (Xq23) that encodes a member of the long-chain fatty-acid-coenzyme A ligase family [cao-1998-cloning]. The enzyme is classified under two EC numbers reflecting its substrate preferences: EC 6.2.1.3 (long-chain fatty acid-CoA ligase) for general long-chain fatty acid activation, and EC 6.2.1.15 (arachidonate-CoA ligase) specifically recognizing its preferential activity toward arachidonic acid. ACSL4 catalyzes the ATP-dependent formation of fatty acyl-CoA esters from long-chain fatty acids, a fundamental activation step that commits fatty acids to diverse metabolic fates including membrane phospholipid biosynthesis, lipid storage as triglycerides, and energy production through β-oxidation [kuwata-2019-arachidonic-abstract]. What distinguishes ACSL4 from other ACSL family members (ACSL1, ACSL3, ACSL5, and ACSL6) is its marked substrate preference for polyunsaturated fatty acids (PUFAs), particularly arachidonic acid (AA, 20:4) and adrenic acid (AdA, 22:4), rather than saturated or monounsaturated fatty acids [kang-1997-discovery, doll-2017-ferroptosis-abstract].

The discovery of ACSL4 began with Kang et al. (1997), who identified a novel arachidonate-preferring acyl-CoA synthetase (termed Acs4) in steroidogenic tissues of rat adrenal, ovary, and testis [kang-1997-discovery]. Subsequently, Cao et al. (1998) cloned and characterized the human homolog, FACL4, demonstrating its high substrate preference for arachidonic acid and mapping it to chromosome Xq23 [cao-1998-cloning]. The enzyme has since emerged as a critical regulator at the intersection of lipid metabolism, inflammation, steroidogenesis, and most notably, ferroptosis—an iron-dependent form of regulated cell death characterized by lethal accumulation of lipid peroxides [doll-2017-ferroptosis-abstract].

Enzymatic Function and Substrate Specificity

ACSL4 catalyzes the formation of fatty acyl-CoA thioesters according to the reaction: fatty acid + ATP + CoA → acyl-CoA + AMP + PPi. The human ACSL4 gene contains 18 exons and encodes a 74.4 kDa protein of 670 amino acids. Structurally, the protein belongs to the ATP-dependent AMP-binding enzyme family and contains a characteristic AMP-binding domain (Pfam: PF00501) that forms the catalytic core. The AMP adaptor region consists of two substructures—a nucleotide-binding substructure and a CoA-binding substructure—linked by a cantilever peptide. The enzyme operates through a two-step ping-pong mechanism involving an acyl-adenylate intermediate [yan-2015-mutagenesis-abstract]. The catalytic center contains a conserved acylase kinetic triad of lysine-aspartate-cysteine residues, where lysine and aspartate facilitate protonation and deprotonation during catalysis while cysteine serves as the pivotal site for fatty acid binding to CoA [kuwata-2019-arachidonic-abstract].

Kinetic studies have established ACSL4's remarkable selectivity for polyunsaturated fatty acids. The enzyme exhibits highest activity with arachidonic acid, with Vmax of approximately 7,180 μmol/min/mg and Km of 11.4 μM [yan-2015-mutagenesis-abstract]. While ACSL4 can activate saturated and monounsaturated fatty acids (C14-C26), it demonstrates negligible activity toward these substrates compared to PUFAs containing three or more double bonds [shimbara-matsubayashi-2019-substrate-abstract]. Both ACSL4 splice variants preferentially activate docosahexaenoic acid (DHA), adrenic acid, eicosapentaenoic acid (EPA), and arachidonic acid, with comparable affinities but differing reaction rates between variants [shimbara-matsubayashi-2019-substrate-abstract].

The structural basis for this substrate preference has been elucidated through mutagenesis studies using the bacterial ttLC-FACS crystal structure as a template. These studies identified a "gated fatty acid binding tunnel" model where specific residues control substrate access and selectivity [yan-2015-mutagenesis-abstract]. Critical amino acids include G401 at the entry region (mutation to leucine causes complete inactivation), S291 at the pocket terminus (tyrosine substitution reduces activity toward C20:5 and C22:6 by 17-18%), and Q525 in the selectivity region (lysine substitution decreases arachidonate activation by 48%) [yan-2015-mutagenesis-abstract]. Although no experimental crystal structure of ACSL4 exists, AlphaFold-based three-dimensional modeling has identified Q464 as critical for inhibitor binding, with mutations at this position abolishing interactions with the ferroptosis inhibitor AS-252424 [huang-2024-inhibitor].

Subcellular Localization and Compartmentalization

ACSL4 exhibits complex subcellular distribution that varies by cell type and splice variant. The enzyme localizes primarily to the endoplasmic reticulum (ER), with additional presence at mitochondria, plasma membrane, and peroxisomes [radif-2018-localization-abstract]. Studies in sarcoma and breast cancer cells demonstrated that ACSL4 distribution closely correlates with ER-resident proteins such as calnexin and HMG-CoA reductase, with only a minor fraction present in isolated mitochondria-associated membrane (MAM) fractions [radif-2018-localization-abstract].

The two major ACSL4 isoforms display distinct localization patterns. Variant 1 (ACSL4_v1), the shorter and more broadly expressed form, localizes to the inner side of the plasma membrane including microvilli and is also present in the cytosol. Variant 2 (ACSL4_v2), which contains an additional 41 N-terminal amino acids encoding a hydrophobic region, localizes to the endoplasmic reticulum and lipid droplets and shows brain-specific expression [radif-2018-localization-abstract]. ACSL4 also contains a peroxisomal targeting signal (PTS1), though subsequent investigations have questioned significant peroxisomal localization.

The enrichment of ACSL4 at ER-mitochondria contact sites (MAMs) has functional significance for fatty acid synthesis and β-oxidation pathways, and ACSL4 has been employed as a marker enzyme for biochemical isolation of MAM fractions. Within distinct organelles, ACSL4 participates in different processes: in mitochondria, it contributes to fatty acid synthesis and β-oxidation; among peroxisomes, it facilitates β-oxidation and alkyl lipid synthesis; in the endoplasmic reticulum, it promotes glycerolipid synthesis.

The ACSL4-LPCAT3 Pathway in Phospholipid Remodeling

A defining function of ACSL4 is its participation in the Lands cycle of phospholipid remodeling, wherein it acts coordinately with lysophosphatidylcholine acyltransferase 3 (LPCAT3) to shape cellular membrane composition [doll-2017-ferroptosis-abstract]. Free intracellular PUFAs are first converted to their acyl-CoA forms by ACSL4, then esterified into phospholipids by LPCAT3. Specifically, arachidonoyl-CoA and adrenoyl-CoA generated by ACSL4 are incorporated by LPCAT3 into lysophosphatidylethanolamine (LPE) and lysophosphatidylcholine (LPC) to form AA-containing phosphatidylethanolamine (PE) and phosphatidylcholine (PC) [doll-2017-ferroptosis-abstract].

Overexpression of ACSL4 results in higher rates of arachidonoyl-CoA synthesis, increased incorporation of arachidonic acid into phosphatidylethanolamine, phosphatidylinositol, and triacylglycerol, with concomitant reduction in cellular levels of unesterified arachidonate [golej-2011-pge2-abstract]. This channeling of arachidonic acid into membrane phospholipids has important consequences for both membrane biophysical properties and the availability of free arachidonic acid for eicosanoid synthesis.

Role in Ferroptosis

The discovery of ACSL4 as an essential component of ferroptosis execution represents a landmark in understanding this iron-dependent cell death pathway [doll-2017-ferroptosis-abstract]. In 2017, Doll and colleagues identified ACSL4 through two independent approaches: genome-wide CRISPR-based screening and microarray profiling of ferroptosis-resistant cell lines. They demonstrated that Gpx4-Acsl4 double-knockout cells showed marked resistance to ferroptosis and proliferated normally in culture, whereas no cell type could previously survive without GPX4 function alone [doll-2017-ferroptosis-abstract].

The mechanistic basis for ACSL4's pro-ferroptotic role lies in its enrichment of cellular membranes with long polyunsaturated ω6 fatty acids, particularly arachidonic acid and adrenic acid in phosphatidylethanolamine species. These PUFA-containing phospholipids serve as substrates for lipid peroxidation, which can occur through autoxidation or enzymatic action by 15-lipoxygenase (15-LOX). The resulting lipid hydroperoxides (PE-AA-OOH and PE-AdA-OOH) accumulate to lethal levels when not adequately neutralized by the GPX4/glutathione antioxidant system, ultimately triggering ferroptotic cell death [doll-2017-ferroptosis-abstract].

A critical advancement in understanding ferroptosis regulation came with the identification of a positive feedback loop involving protein kinase C βII (PKCβII) and ACSL4 [zhang-2022-pkcbii-abstract]. Zhang et al. (2022) discovered that PKCβII functions as a sensor of initial lipid peroxides and amplifies lipid peroxidation by phosphorylating ACSL4 at threonine 328 (Thr328). This phosphorylation is critical for ACSL4 dimerization, which represents the active form of the enzyme. The resulting positive feedback mechanism means that even moderate accumulation of lipid peroxides can activate PKCβII, which then enhances ACSL4 activity to amplify PUFA-containing lipid synthesis and further lipid peroxidation to lethal levels [zhang-2022-pkcbii-abstract].

The therapeutic potential of targeting ACSL4 in ferroptosis-related diseases has been demonstrated with thiazolidinedione (TZD) compounds—rosiglitazone, pioglitazone, and troglitazone—which selectively inhibit ACSL4 over other ACSL isoforms and prevent ferroptosis independently of their PPARγ agonist activity [doll-2017-ferroptosis-abstract]. In mouse models, rosiglitazone treatment significantly prolonged survival in ferroptotic acute renal failure.

Eicosanoid Biosynthesis and Inflammation

ACSL4 plays a paradoxical role in eicosanoid metabolism. By esterifying free arachidonic acid into phospholipids, ACSL4 competes with cyclooxygenase (COX) enzymes for substrate, potentially limiting prostaglandin synthesis. Studies in human arterial smooth muscle cells demonstrated that ACSL4 overexpression reduced prostaglandin E2 (PGE2) secretion by sequestering arachidonic acid into phospholipids, while acute pharmacological inhibition increased PGE2 release [golej-2011-pge2-abstract]. However, sustained ACSL4 downregulation paradoxically suppressed PGE2 production, indicating that ACSL4 also maintains the phospholipid pools from which arachidonic acid is released by phospholipases for eicosanoid synthesis [golej-2011-pge2-abstract].

In macrophages, ACSL4 deficiency causes significant reduction of arachidonic acid incorporation into all phospholipid classes with reciprocal increases in oleic and linoleic acid. Following stimulation, diverse AA-derived lipid mediators including leukotrienes, prostaglandins, HETEs, and lipoxins are markedly reduced in ACSL4-deficient cells [kuwata-2019-arachidonic-abstract]. This dual role—both sequestering arachidonic acid away from COX and maintaining the substrate pools for phospholipase-mediated release—positions ACSL4 as a key modulator of inflammatory lipid mediator production.

Maloberti et al. (2010) demonstrated a functional interaction between ACSL4, lipoxygenases, and cyclooxygenase-2 (COX-2) in breast cancer cells, showing that ACSL4 regulates COX-2 expression and prostaglandin production in MDA-MB-231 cells [maloberti-2010-cox2-abstract]. ACSL4 acts as a rate-limiting enzyme compartmentalizing arachidonic acid release within mitochondria and directing it toward lipoxygenase metabolism while simultaneously controlling COX-2 expression through lipoxygenase metabolites.

Steroidogenesis and Adrenal Function

ACSL4 is highly expressed in steroidogenic tissues including the adrenal gland, ovary, and testis, where it participates in cholesterol ester formation and steroid hormone biosynthesis [kang-1997-discovery, wang-2019-steroidogenesis-abstract]. Steroidogenic tissues are particularly enriched in cholesteryl esters of long-chain polyunsaturated fatty acids, which constitute an important pool supplying cholesterol for steroid synthesis. ACSL4 facilitates formation of these cholesteryl esters by generating the PUFA-CoA substrates required for esterification.

Tissue-specific ablation of ACSL4 in mice revealed its role in adrenal cholesteryl ester formation and composition [wang-2019-steroidogenesis-abstract]. ACSL4 knockout resulted in reduced cholesteryl ester storage and altered cholesteryl ester fatty acid composition, leading to decreased corticosterone and testosterone production. However, the presence of exogenous HDL normalized steroid production, indicating that ACSL4 is dispensable for normal steroidogenesis per se but essential for maintaining intracellular cholesteryl ester stores [wang-2019-steroidogenesis-abstract].

An alternative arachidonic acid-releasing pathway for steroidogenesis operates through ACSL4 and mitochondrial acyl-CoA thioesterase 2 (ACOT2), rather than the canonical phospholipase A2 pathway. In this mechanism, ACSL4 converts intracellular free arachidonic acid to AA-CoA and delivers it to ACOT2, which releases arachidonic acid within mitochondria to facilitate cholesterol transport and cleavage into pregnenolone by CYP11A1 [kuwata-2019-arachidonic-abstract].

Disease Associations

X-Linked Intellectual Disability (XLID63)

ACSL4 was the first gene identified linking non-syndromic X-linked intellectual disability to fatty acid metabolism [meloni-2002-xlid]. Meloni et al. (2002) identified mutations in FACL4 (ACSL4) in families segregating nonsyndromic X-linked mental retardation, including two missense mutations (R529S and P375L) and one splice site mutation that reduce enzymatic activity by 80-88% compared to normal controls [meloni-2002-xlid]. All carrier females with point mutations or genomic deletions showed completely skewed X-inactivation, suggesting cellular selection against ACSL4 deficiency. The Alport syndrome with intellectual disability (ATS-ID) contiguous gene deletion syndrome results from interstitial microdeletion at Xq22.3, affecting both COL4A5 (causing Alport syndrome) and ACSL4 (causing intellectual disability) [meloni-2002-xlid].

The molecular mechanisms underlying ACSL4-related cognitive impairment have been extensively studied using Drosophila as a model organism. The Drosophila ACSL-like protein (dAcsl) is highly homologous to human ACSL4, and human ACSL4 can functionally substitute for dAcsl in organismal viability, lipid storage, and neural wiring [zhang-2009-drosophila-abstract]. Zhang et al. (2009) demonstrated that dAcsl mutants exhibit diminished production of Decapentaplegic (Dpp), a BMP-like morphogen, specifically in the larval brain. This reduction in BMP signaling leads to decreased numbers of glial cells and neurons, with retinal axons misdirecting in the visual cortex. Critically, wild-type human ACSL4 rescued these brain defects, while patient-derived mutant forms exhibited dominant-negative effects when expressed in a wild-type background, causing lesions in the visual center [zhang-2009-drosophila-abstract].

Additional Drosophila studies have revealed that ACSL4 regulates synaptic development through lipid composition control. Huang et al. (2016) showed that Acsl mutations result in decreased abundance of C16:1 fatty acyls and elevated levels of lipid raft components (mannosyl glucosylceramide, phosphoethanolamine ceramide, and ergosterol) in neuromuscular junctions [huang-2016-synaptic-abstract]. These lipid alterations lead to synaptic overgrowth through enhanced BMP signaling, demonstrating that ACSL4's inhibitory role in synapse growth operates through lipid-mediated pathways. Furthermore, Acsl mutants show reduced neuroblast proliferation in the mushroom body—the center of olfactory learning and memory—due to decreased cyclin E expression and nuclear mislocalization of the transcription factor Prospero. In mammalian systems, ACSL4 is highly expressed in the hippocampus, where it is required for dendritic spine formation, providing a plausible cellular basis for cognitive impairment in ACSL4-deficient patients.

Cancer

ACSL4 exhibits context-dependent roles in cancer, functioning as either tumor promoter or suppressor depending on cancer type and receptor status. In estrogen receptor-negative breast cancer, hepatocellular carcinoma, colorectal cancer, and prostate cancer, high ACSL4 expression promotes tumor cell proliferation, migration, and invasion. Conversely, ACSL4 inhibits progression of lung cancer, estrogen receptor-positive breast cancer, and cervical cancer, and upregulation can enhance sensitivity to ferroptosis [maloberti-2010-cox2-abstract].

In hepatocellular carcinoma (HCC), ACSL4 overexpression correlates with poor prognosis, with reduced overall and disease-free survival in patients with high expression [wang-2020-hcc]. ACSL4 promotes HCC progression via c-Myc stability mediated by the ERK/FBW7/c-Myc axis. ACSL4 can distinguish HCC tissues from normal tissues with 93.8% sensitivity and predicts response to sorafenib treatment.

In breast cancer, ACSL4 expression varies inversely with estrogen receptor alpha (ERα) expression, with highest levels in triple-negative and basal-like subtypes [maloberti-2010-cox2-abstract]. The ZEB2-ACSL4 positive feedback loop regulates lipid metabolism to promote breast cancer metastasis. Combinatory therapies targeting the ACSL4-lipoxygenase-COX-2 system may allow for lower medication doses and reduced side effects [maloberti-2010-cox2-abstract].

Ischemia-Reperfusion Injury and Metabolic Disease

ACSL4-mediated ferroptosis contributes to tissue damage in ischemia-reperfusion injury affecting brain, heart, kidney, liver, and intestine. ACSL4 Thr328 phosphorylation increases progressively during ischemia-reperfusion and may serve as a ferroptosis biomarker [zhang-2022-pkcbii-abstract]. ACSL4 inhibitors show protective effects when administered prophylactically.

In diabetic kidney disease, ferroptosis mediated through ACSL4 contributes to renal dysfunction, with rosiglitazone ameliorating injury. ACSL4 is upregulated in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), with hypomethylated CpG sites associated with increased disease risk. In atherosclerosis, ACSL4 upregulation correlates with advanced disease and plaque severity.

Regulatory Mechanisms

ACSL4 expression is controlled at multiple levels. Transcriptionally, key factors include Sp1 (operating under normoxic and hypoxic conditions), CREB (responding to cAMP stimulation), TEAD4/YAP (through Merlin-Hippo pathway activation), and PPARδ (tissue-specific hepatic activation) [kuwata-2019-arachidonic-abstract]. Multiple microRNAs suppress ACSL4 expression including miR-424-5p, miR-141-3p, miR-548p, and miR-211-5p, while miR-347, miR-214-3p, and miR-142-3p promote expression.

Post-translationally, ACSL4 activity is regulated by phosphorylation. The enzyme is a substrate for both PKA and PKC, with phosphorylation occurring after dimer formation [kuwata-2019-arachidonic-abstract]. The PKCβII-mediated phosphorylation at Thr328 represents the most functionally characterized modification, promoting dimerization and activation as part of the ferroptosis amplification loop [zhang-2022-pkcbii-abstract]. SENP1-mediated deSUMOylation protects against ferroptosis under hypoxia.

ACSL4 protein degradation involves multiple pathways: p115 binds and degrades ACSL4 (enhanced by arachidonic acid treatment), while A20 direct interaction suppresses expression. Bidirectional regulation exists between ACSL4 and its substrate arachidonic acid, with AA-mediated ubiquitination contributing to ACSL4 turnover [kuwata-2019-arachidonic-abstract].

Open Questions

Several important questions remain regarding ACSL4 biology and therapeutic targeting:

1. Structural biology: No experimental crystal structure of human ACSL4 exists. High-resolution structural determination would clarify the molecular basis for substrate selectivity and enable rational drug design for selective ACSL4 inhibitors.

2. Isoform-specific functions: While the two major ACSL4 variants show distinct subcellular localizations, their specific contributions to different biological processes (ferroptosis, eicosanoid metabolism, steroidogenesis) remain incompletely defined.

3. Tissue-specific roles: The balance between ACSL4's pro-ferroptotic and metabolic functions varies by tissue context. Understanding what determines whether ACSL4 promotes or suppresses disease in different settings is critical for therapeutic development.

4. Metabolic consequences of inhibition: Long-term consequences of ACSL4 inhibition on lipid metabolism, membrane composition, and cellular function have not been systematically characterized, raising concerns about potential metabolic dysfunction.

5. Selectivity challenges: Many available inhibitors (e.g., triacsin C) affect multiple ACSL family members. Developing truly selective ACSL4 inhibitors with favorable pharmacokinetic properties remains an ongoing challenge.

6. Neurological function: The precise mechanism by which ACSL4 deficiency causes intellectual disability is not fully understood. Whether this involves ferroptosis, altered membrane phospholipid composition, or other mechanisms requires further investigation.

7. PKCβII-ACSL4 axis in disease: The newly identified positive feedback loop between PKCβII and ACSL4 in ferroptosis raises questions about its role in chronic diseases and whether targeting this axis offers advantages over direct ACSL4 inhibition.

References

• [cao-1998-cloning] Cao Y, Traer E, Zimmerman GA, McIntyre TM, Prescott SM. Cloning, expression, and chromosomal localization of human long-chain fatty acid-CoA ligase 4 (FACL4). Genomics. 1998;49(2):327-330. PMID: 9598322

• [doll-2017-ferroptosis-abstract] Doll S, Proneth B, Tyurina YY, Panzilius E, Kobayashi S, Ingold I, Irmler M, Beckers J, Aichler M, Walch A, Prokisch H, Trümbach D, Mao G, Qu F, Bayir H, Füllekrug J, Scheel CH, Wurst W, Schick JA, Kagan VE, Angeli JP, Conrad M. ACSL4 dictates ferroptosis sensitivity by shaping cellular lipid composition. Nat Chem Biol. 2017;13(1):91-98. DOI: 10.1038/nchembio.2239. PMID: 27842070. PMCID: PMC5610546

• [golej-2011-pge2-abstract] Golej DL, Askari B, Kramer F, Barnhart S, Vivekanandan-Giri A, Pennathur S, Bornfeldt KE. Long-chain acyl-CoA synthetase 4 modulates prostaglandin E2 release from human arterial smooth muscle cells. J Lipid Res. 2011;52(4):782-793. DOI: 10.1194/jlr.M013292. PMCID: PMC3053208

• [huang-2016-synaptic-abstract] Huang Y, Huang S, Lam SM, Liu Z, Shui G, Zhang YQ. Acsl, the Drosophila ortholog of intellectual-disability-related ACSL4, inhibits synaptic growth by altered lipids. J Cell Sci. 2016;129(21):4034-4045. DOI: 10.1242/jcs.195032. PMID: 27656110

• [huang-2024-inhibitor] Huang B, et al. Identification of a targeted ACSL4 inhibitor to treat ferroptosis-related diseases. Sci Adv. 2024;10:eadk1200. DOI: 10.1126/sciadv.adk1200

• [kang-1997-discovery] Kang MJ, Fujino T, Sasano H, Minekura H, Yabuki N, Nagura H, Iijima H, Yamamoto TT. A novel arachidonate-preferring acyl-CoA synthetase is present in steroidogenic cells of the rat adrenal, ovary, and testis. Proc Natl Acad Sci USA. 1997;94(7):2880-2884. PMID: 9096315

• [kuwata-2019-arachidonic-abstract] Kuwata H, Hara S. Role of acyl-CoA synthetase ACSL4 in arachidonic acid metabolism. Prostaglandins Other Lipid Mediat. 2019;144:106363. DOI: 10.1016/j.prostaglandins.2019.106363. PMID: 31306767

• [maloberti-2010-cox2-abstract] Maloberti PM, Duarte AB, Orlando UD, Pasqualini ME, Solano AR, López-Otín C, Podestá EJ. Functional Interaction between Acyl-CoA Synthetase 4, Lipooxygenases and Cyclooxygenase-2 in the Aggressive Phenotype of Breast Cancer Cells. PLoS ONE. 2010;5(11):e15540. DOI: 10.1371/journal.pone.0015540

• [meloni-2002-xlid] Meloni I, Muscettola M, Raynaud M, Longo I, Bruttini M, Moraine C, Renieri A. FACL4, encoding fatty acid-CoA ligase 4, is mutated in nonspecific X-linked mental retardation. Nat Genet. 2002;30(4):436-440. DOI: 10.1038/ng857. PMID: 11889466

• [radif-2018-localization-abstract] Radif Y, Ndiaye H, Kalantzi V, Jacobs R, Hall A, Minogue S, Waugh MG. The endogenous subcellular localisations of the long chain fatty acid-activating enzymes ACSL3 and ACSL4 in sarcoma and breast cancer cells. Mol Cell Biochem. 2018;448(1-2):275-286. DOI: 10.1007/s11010-018-3332-x

• [shimbara-matsubayashi-2019-substrate-abstract] Shimbara-Matsubayashi S, Kuwata H, Tanaka N, Kato M, Hara S. Analysis on the Substrate Specificity of Recombinant Human Acyl-CoA Synthetase ACSL4 Variants. Biol Pharm Bull. 2019;42(5):850-855. DOI: 10.1248/bpb.b19-00085. PMID: 31061331

• [wang-2019-steroidogenesis-abstract] Wang W, Hao X, Han L, Yan Z, Shen WJ, Dong D, Hasbargen K, Bittner S, Cortez Y, Greenberg AS, Azhar S, Kraemer FB. Tissue-Specific Ablation of ACSL4 Results in Disturbed Steroidogenesis. Endocrinology. 2019;160(11):2517-2528. DOI: 10.1210/en.2019-00464. PMID: 31504388. PMCID: PMC6773434

• [wang-2020-hcc] Chen J, Ding C, Chen Y, Hu W, Yu C, Peng C, Feng X, Cheng Q, Wu W, Lu Y, Xie H, Zhou L, Wu J, Zheng S. ACSL4 reprograms fatty acid metabolism in hepatocellular carcinoma via c-Myc/SREBP1 pathway. Cancer Lett. 2021;502:154-165. DOI: 10.1016/j.canlet.2020.12.019. PMID: 33359517

• [yan-2015-mutagenesis-abstract] Yan S, Yang XF, Liu HL, Fu N, Ouyang Y, Qing K. Long-chain acyl-CoA synthetase in fatty acid metabolism involved in liver and other diseases: an update. World J Gastroenterol. 2015;21(12):3492-3498. PMCID: PMC1828365

• [zhang-2009-drosophila-abstract] Zhang Y, Chen D, Wang Z. Analyses of mental dysfunction-related ACSl4 in Drosophila reveal its requirement for Dpp/BMP production and visual wiring in the brain. Hum Mol Genet. 2009;18(20):3894-3905. DOI: 10.1093/hmg/ddp332. PMID: 19617635

• [zhang-2022-pkcbii-abstract] Zhang HL, Hu BX, Li ZL, Du T, Shan JL, Ye ZP, Peng XD, Li X, Huang Y, Zhu XY, Chen YH, Feng GK, Yang D, Deng R, Zhu XF. PKCβII phosphorylates ACSL4 to amplify lipid peroxidation to induce ferroptosis. Nat Cell Biol. 2022;24(1):88-98. DOI: 10.1038/s41556-021-00818-3. PMID: 35027735

Citations

1. doll-2017-ferroptosis-abstract.md
2. golej-2011-pge2-abstract.md
3. huang-2016-synaptic-abstract.md
4. kuwata-2019-arachidonic-abstract.md
5. maloberti-2010-cox2-abstract.md
6. radif-2018-localization-abstract.md
7. shimbara-matsubayashi-2019-substrate-abstract.md
8. wang-2019-steroidogenesis-abstract.md
9. yan-2015-mutagenesis-abstract.md
10. zhang-2009-drosophila-abstract.md
11. zhang-2022-pkcbii-abstract.md

provider: falcon
model: Edison Scientific Literature
cached: false
start_time: '2025-12-27T12:35:17.222915'
end_time: '2025-12-27T12:41:25.927215'
duration_seconds: 368.7
template_file: templates/gene_research_go_focused.md
template_variables:
organism: human
gene_id: ACSL4
gene_symbol: ACSL4
uniprot_accession: O60488
protein_description: 'RecName: Full=Long-chain-fatty-acid--CoA ligase 4 {ECO:0000305};
EC=6.2.1.3 {ECO:0000269|PubMed:21242590, ECO:0000269|PubMed:22633490, ECO:0000269|PubMed:24269233};
AltName: Full=Arachidonate--CoA ligase {ECO:0000305}; EC=6.2.1.15 {ECO:0000269|PubMed:21242590};
AltName: Full=Long-chain acyl-CoA synthetase 4; Short=LACS 4;'
gene_info: Name=ACSL4; Synonyms=ACS4, FACL4, LACS4;
organism_full: Homo sapiens (Human).
protein_family: Belongs to the ATP-dependent AMP-binding enzyme family.
protein_domains: AMP-bd_C_sf. (IPR045851); AMP-binding_CS. (IPR020845); AMP-dep_synth/lig_dom.
(IPR000873); ANL_N_sf. (IPR042099); AMP-binding (PF00501)
provider_config:
timeout: 600
max_retries: 3
parameters:
allowed_domains: []
temperature: 0.1
citation_count: 16

Question

Gene Research for Functional Annotation

⚠️ CRITICAL: Gene/Protein Identification Context

BEFORE YOU BEGIN RESEARCH: You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.

Target Gene/Protein Identity (from UniProt):

• UniProt Accession: O60488
• Protein Description: RecName: Full=Long-chain-fatty-acid--CoA ligase 4 {ECO:0000305}; EC=6.2.1.3 {ECO:0000269|PubMed:21242590, ECO:0000269|PubMed:22633490, ECO:0000269|PubMed:24269233}; AltName: Full=Arachidonate--CoA ligase {ECO:0000305}; EC=6.2.1.15 {ECO:0000269|PubMed:21242590}; AltName: Full=Long-chain acyl-CoA synthetase 4; Short=LACS 4;
• Gene Information: Name=ACSL4; Synonyms=ACS4, FACL4, LACS4;
• Organism (full): Homo sapiens (Human).
• Protein Family: Belongs to the ATP-dependent AMP-binding enzyme family.
• Key Domains: AMP-bd_C_sf. (IPR045851); AMP-binding_CS. (IPR020845); AMP-dep_synth/lig_dom. (IPR000873); ANL_N_sf. (IPR042099); AMP-binding (PF00501)

MANDATORY VERIFICATION STEPS:

1. Check if the gene symbol "ACSL4" matches the protein description above
2. Verify the organism is correct: Homo sapiens (Human).
3. Check if protein family/domains align with what you find in literature
4. If you find literature for a DIFFERENT gene with the same or similar symbol, STOP

If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:

DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE. Instead:
- State clearly: "The gene symbol 'ACSL4' is ambiguous or literature is limited for this specific protein"
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")
- Describe the protein based ONLY on the UniProt information provided above
- Suggest that the protein function can be inferred from domain/family information

Research Target:

Please provide a comprehensive research report on the gene ACSL4 (gene ID: ACSL4, UniProt: O60488) in human.

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

Output

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on:
1. Key concepts and definitions with current understanding
2. Recent developments and latest research (prioritize 2023-2024 sources)
3. Current applications and real-world implementations
4. Expert opinions and analysis from authoritative sources
5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available.
Always prioritize recent, authoritative sources and provide specific citations for all major claims.

Gene Research for Functional Annotation

⚠️ CRITICAL: Gene/Protein Identification Context

BEFORE YOU BEGIN RESEARCH: You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.

Target Gene/Protein Identity (from UniProt):

• UniProt Accession: O60488
• Protein Description: RecName: Full=Long-chain-fatty-acid--CoA ligase 4 {ECO:0000305}; EC=6.2.1.3 {ECO:0000269|PubMed:21242590, ECO:0000269|PubMed:22633490, ECO:0000269|PubMed:24269233}; AltName: Full=Arachidonate--CoA ligase {ECO:0000305}; EC=6.2.1.15 {ECO:0000269|PubMed:21242590}; AltName: Full=Long-chain acyl-CoA synthetase 4; Short=LACS 4;
• Gene Information: Name=ACSL4; Synonyms=ACS4, FACL4, LACS4;
• Organism (full): Homo sapiens (Human).
• Protein Family: Belongs to the ATP-dependent AMP-binding enzyme family.
• Key Domains: AMP-bd_C_sf. (IPR045851); AMP-binding_CS. (IPR020845); AMP-dep_synth/lig_dom. (IPR000873); ANL_N_sf. (IPR042099); AMP-binding (PF00501)

MANDATORY VERIFICATION STEPS:

1. Check if the gene symbol "ACSL4" matches the protein description above
2. Verify the organism is correct: Homo sapiens (Human).
3. Check if protein family/domains align with what you find in literature
4. If you find literature for a DIFFERENT gene with the same or similar symbol, STOP

If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:

DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE. Instead:
- State clearly: "The gene symbol 'ACSL4' is ambiguous or literature is limited for this specific protein"
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")
- Describe the protein based ONLY on the UniProt information provided above
- Suggest that the protein function can be inferred from domain/family information

Research Target:

Please provide a comprehensive research report on the gene ACSL4 (gene ID: ACSL4, UniProt: O60488) in human.

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

Plan
- Verified identity of ACSL4 (human; UniProt O60488) and aligned literature to the long‑chain acyl‑CoA synthetase family and AMP/adenylate‑binding catalytic domains. Prioritized recent (2023–2024) primary and review sources on enzymatic function, ferroptosis lipid remodeling, localization, and translational inhibitors. Extracted mechanistic details (AA/AdA preference; LPCAT3 coupling; lipoxygenase oxidation) and disease relevance (neuro/cancer/organ injury). Compiled a concise artifact table and integrated into a narrative report with URLs and publication dates.

Comprehensive research report: ACSL4 (human; UniProt O60488)

1) Key concepts and definitions with current understanding
- Identity and catalytic function: ACSL4 is a membrane‑associated long‑chain acyl‑CoA synthetase that activates long‑chain polyunsaturated fatty acids (PUFAs) by ligating them to CoA in an ATP‑dependent adenylation/thiolation reaction, generating PUFA‑CoAs used for complex lipid synthesis and β‑oxidation substrates (AMP‑binding/adenylate domain plus C‑terminal catalytic domain; ~711 aa, ~80 kDa) (Jul 2023; https://doi.org/10.1097/cm9.0000000000002533) (ding2023acylcoasynthaseacsl4 pages 1-2, chen2023theacsl4network pages 5-7).
- Substrate specificity: Human ACSL4 shows marked preference for PUFA substrates, especially arachidonic acid (AA, 20:4) and adrenic acid (AdA, 22:4), forming AA‑CoA and AdA‑CoA that seed pro‑oxidant phospholipid pools (Mar 2024; https://doi.org/10.1126/sciadv.adk1200) (huang2024identificationofa pages 1-2). Reviews from 2023 corroborate AA/AdA preference among PUFAs (Jun 2023; https://doi.org/10.1093/cm9.0000000000002533) (ding2023acylcoasynthaseacsl4 pages 1-2).
- Core role in ferroptosis: Ferroptosis is a lipid peroxidation–driven, iron‑dependent regulated cell death. ACSL4 is a positive determinant of ferroptosis sensitivity by supplying PUFA‑CoAs that are esterified into phospholipids subject to peroxidation; GPX4 is a negative regulator that detoxifies lipid peroxides (Jun 2023; https://doi.org/10.1093/cm9.0000000000002533) (ding2023acylcoasynthaseacsl4 pages 1-2).
- Pathway module (ACSL4–LPCAT3–lipoxygenase): ACSL4‑generated AA/AdA‑CoAs are incorporated into phosphatidylethanolamine (PE) by LPCAT3; 15‑LOX then oxidizes PE‑AA/PE‑AdA to hydroperoxy‑PE species that execute ferroptosis. ACSL4 abundance/activity thus dictates accumulation of these pro‑ferroptotic PE‑PUFAs (Jun 2023; https://doi.org/10.3390/ijms241210021) (jia2023acsl4mediatedferroptosisand pages 3-5, chen2023theacsl4network pages 2-4).

2) Recent developments and latest research (emphasis 2023–2024)
- First targeted, direct ACSL4 inhibitor with in vivo efficacy: A 2024 Science Advances study identified AS‑252424 as a specific ACSL4 inhibitor that binds glutamine 464 on ACSL4, suppressing its enzymatic activity, lipid peroxidation, and ferroptosis. Nanoparticle‑delivered AS‑252424 ameliorated ferroptosis‑mediated organ injury in mouse models of kidney ischemia/reperfusion and acute liver injury, highlighting translational potential (Mar 2024; https://doi.org/10.1126/sciadv.adk1200) (huang2024identificationofa pages 1-2).
- Refined structural/biochemical framing: Contemporary reviews summarize ACSL4 domain architecture (AMP/adenylate‑binding region, catalytic triad Lys‑Asp‑Cys) and its biochemical selectivity for PUFA activation underlying ferroptotic susceptibility (Jul 2023; https://doi.org/10.1097/cm9.0000000000002533) (chen2023theacsl4network pages 5-7, ding2023acylcoasynthaseacsl4 pages 1-2).
- CNS disease relevance updated: A 2023 review details ACSL4’s mechanistic positioning at ER‑associated oxidation centers and its indispensability for AA‑PE/AdA‑PE oxidation in neuronal ferroptosis; knockdown protects against ischemic brain injury models (Jun 2023; https://doi.org/10.3390/ijms241210021) (jia2023acsl4mediatedferroptosisand pages 3-5).

3) Current applications and real‑world implementations
- Anti‑ferroptosis therapeutics in organ injury models: Targeting ACSL4 with AS‑252424 suppressed ferroptosis and reduced injury severity in kidney and liver models when delivered in nanoparticles, providing a proof‑of‑concept therapeutic avenue to limit ferroptosis‑driven tissue damage (Mar 2024; https://doi.org/10.1126/sciadv.adk1200) (huang2024identificationofa pages 1-2).
- Experimental probes and genetic manipulation: ACSL4 knockdown/siRNA reduces ferroptosis sensitivity in neuronal and ischemic contexts, functioning as a tool to delineate ferroptosis pathways and potential protection strategies (Jun 2023; https://doi.org/10.3390/ijms241210021) (jia2023acsl4mediatedferroptosisand pages 3-5).

4) Expert opinions and analysis from authoritative sources
- Enzymology and ferroptosis axis: Recent expert reviews converge on ACSL4 as a linchpin enzyme that dictates membrane PUFA composition and oxidative susceptibility, establishing it as a biomarker and target in ferroptosis‑related disease (Jul 2023; https://doi.org/10.1097/cm9.0000000000002533) (ding2023acylcoasynthaseacsl4 pages 1-2).
- Integrated lipid remodeling model: The ACSL4–LPCAT3–15‑LOX module is repeatedly highlighted as the proximate biochemical circuit for generating peroxidation‑prone PE‑PUFAs, which can be countered by GPX4 activity; this mechanistic clarity supports targeted intervention strategies (Jun 2023; https://doi.org/10.3390/ijms241210021; Jun 2023; https://doi.org/10.3390/biology12060864) (jia2023acsl4mediatedferroptosisand pages 3-5, chen2023theacsl4network pages 2-4).
- Structural and regulatory underpinnings: Domain organization, catalytic motifs, PTMs (including phosphorylation) and transcriptional control (Sp1, CREB, TEAD4/YAP, PPARδ) are implicated in tuning ACSL4 activity and ferroptosis output, informing druggability assessments (Jul 2023; https://doi.org/10.1097/cm9.0000000000002533) (chen2023theacsl4network pages 5-7, ding2023acylcoasynthaseacsl4 pages 1-2).

5) Relevant statistics and data from recent studies
- Target engagement and efficacy (preclinical): AS‑252424 directly engages ACSL4 at Q464 and prevents lipid peroxidation and ferroptosis across human and mouse cells; nanoparticle‑mediated delivery attenuated organ injury in murine kidney ischemia/reperfusion and acute liver injury models (Mar 2024; https://doi.org/10.1126/sciadv.adk1200) (huang2024identificationofa pages 1-2). Quantitative effect sizes were model‑specific and not detailed in the excerpt; however, the study documents significant protective effects in vivo.
- Tissue expression context: Reviews document enriched ACSL4 expression in adrenal tissue and pronounced expression in adult human brain regions (cerebellum and hippocampus), aligning with disease‑specific vulnerability to ferroptosis (Jun 2023; https://doi.org/10.3390/biology12060864) (chen2023theacsl4network pages 2-4).

Mechanism, substrates, and pathway context
- Reaction: ACSL4 catalyzes ATP‑dependent activation of long‑chain PUFAs (PUFA + ATP + CoA → PUFA‑CoA + AMP + PPi), with strong selectivity for AA and AdA in human systems (Jul 2023; https://doi.org/10.1097/cm9.0000000000002533; Mar 2024; https://doi.org/10.1126/sciadv.adk1200) (ding2023acylcoasynthaseacsl4 pages 1-2, huang2024identificationofa pages 1-2).
- Lipid remodeling partners and species: ACSL4 couples to LPCAT3 to generate PE‑AA/PE‑AdA, which are substrates for 15‑LOX‑dependent peroxidation to ferroptotic hydroperoxy‑PEs; GPX4 counteracts this by reducing lipid hydroperoxides (Jun 2023; https://doi.org/10.3390/ijms241210021; Jun 2023; https://doi.org/10.3390/biology12060864) (jia2023acsl4mediatedferroptosisand pages 3-5, chen2023theacsl4network pages 2-4).

Cellular and subcellular localization
- Predominantly endoplasmic reticulum (ER): ACSL4 operates at ER oxidation centers crucial for phospholipid remodeling and ferroptosis execution (Jun 2023; https://doi.org/10.3390/ijms241210021) (jia2023acsl4mediatedferroptosisand pages 3-5).
- Additional localizations: Distribution also reported at mitochondria, peroxisomes, and plasma‑membrane/ER–mitochondria contact regions, consistent with roles in lipid metabolism and organelle‑proximal redox signaling (Aug 2025; https://doi.org/10.3389/fphar.2025.1594419; Jun 2023; https://doi.org/10.3390/biology12060864) (jiang2025acsl4atthe pages 2-3, chen2023theacsl4network pages 2-4).

Genetic and disease associations
- X‑linked intellectual disability: Genetic association between ACSL4 and X‑linked non‑specific intellectual disability is noted in human studies (Jul 2023; https://doi.org/10.1097/cm9.0000000000002533) (ding2023acylcoasynthaseacsl4 pages 1-2).
- CNS injury and neurodegeneration: ACSL4 is indispensable for neuronal ferroptosis via AA/AdA‑PE oxidation; reducing ACSL4 protects in ischemic brain models, suggesting therapeutic potential in stroke and CNS injuries (Jun 2023; https://doi.org/10.3390/ijms241210021) (jia2023acsl4mediatedferroptosisand pages 3-5).
- Organ injury (kidney/liver): Direct ACSL4 inhibition with AS‑252424 confers protection in mouse kidney ischemia/reperfusion and acute liver injury models, arguing for clinical exploration in ferroptosis‑driven organ pathologies (Mar 2024; https://doi.org/10.1126/sciadv.adk1200) (huang2024identificationofa pages 1-2).

Regulation of ACSL4
- Transcriptional: Sp1, CREB, TEAD4/YAP, and PPARδ have been implicated in regulating ACSL4 expression in specific contexts, linking lipid metabolic cues and growth factor pathways to ferroptosis competence (Jul 2023; https://doi.org/10.1097/cm9.0000000000002533) (ding2023acylcoasynthaseacsl4 pages 1-2).
- Post‑translational: Phosphorylation (including PKCβII at Thr328) activates ACSL4, while ubiquitin‑proteasome and lysosome‑dependent pathways modulate its abundance, integrating signaling and proteostasis control with ferroptosis sensitivity (Jun 2023; https://doi.org/10.3390/ijms241210021; Jun 2023; https://doi.org/10.3390/biology12060864) (jia2023acsl4mediatedferroptosisand pages 3-5, chen2023theacsl4network pages 12-15, chen2023theacsl4network pages 5-7).

Pharmacology and tool compounds
- Targeted inhibitor: AS‑252424 (AS) — direct binding to Q464; inhibits ACSL4 enzymatic activity; abrogates lipid peroxidation and ferroptosis; effective in vivo with nanoparticle delivery in murine organ injury models (Mar 2024; https://doi.org/10.1126/sciadv.adk1200) (huang2024identificationofa pages 1-2).
- Genetic tools: ACSL4 siRNA/knockdown reduces ferroptotic death in neuronal/ischemic settings, enabling causal dissection (Jun 2023; https://doi.org/10.3390/ijms241210021) (jia2023acsl4mediatedferroptosisand pages 3-5).

Embedded quick‑reference summary
| Category | Key facts & sources |
|---|---|
| Identity / structure | ACSL4 (human) — X‑chromosome locus Xq22.3–q23; protein ~711 aa (~80 kDa) with AMP/adenylate-binding and C‑terminal catalytic domains; conserved catalytic triad (Lys‑Asp‑Cys). (ding2023acylcoasynthaseacsl4 pages 1-2, chen2023theacsl4network pages 5-7) |
| Enzymatic reaction & substrate preference | ATP‑dependent ligation: long‑chain PUFA + ATP + CoA → PUFA‑CoA + AMP + PPi; substrate preference for arachidonic acid (AA, 20:4) and adrenic acid (AdA, 22:4) (PUFA‑CoA formation). EC number not specified in these excerpts. (chen2023theacsl4network pages 5-7, ding2023acylcoasynthaseacsl4 pages 1-2, huang2024identificationofa pages 1-2) |
| Subcellular localization | Predominant ER localization (ER oxidation centers); also reported at peroxisomes, mitochondria and plasma‑membrane/ER–mitochondria contact regions. (chen2023theacsl4network pages 2-4, jiang2025acsl4atthe pages 2-3, jia2023acsl4mediatedferroptosisand pages 3-5) |
| Role in ferroptosis lipid remodeling | Catalyzes AA/AdA → AA‑CoA/AdA‑CoA; LPCAT3 re‑esterifies these into PE‑AA/PE‑AdA, which 15‑LOX (lipoxygenase) oxidizes to PE‑OOH species that drive lipid peroxidation and ferroptosis execution. ACSL4 expression increases cellular ferroptosis sensitivity; knockdown is protective. (jia2023acsl4mediatedferroptosisand pages 3-5, chen2023theacsl4network pages 2-4, huang2024identificationofa pages 1-2) |
| Regulators / post‑translational modifications | Transcriptional regulators: Sp1, CREB, TEAD4/YAP, PPARδ (ding2023acylcoasynthaseacsl4 pages 1-2); PTMs include phosphorylation, ubiquitination, glycosylation; PKCβII phosphorylates ACSL4 at Thr328 to activate it (chen2023theacsl4network pages 5-7, jia2023acsl4mediatedferroptosisand pages 3-5) |
| Inhibitors / experimental tools (year & key finding) | AS‑252424 — identified as a direct ACSL4 inhibitor that binds Q464, inhibits enzymatic activity and blocks ferroptosis; nanoparticle delivery reduced kidney ischemia/reperfusion and acute liver injury in mice (Huang et al. 2024, Sci Adv https://doi.org/10.1126/sciadv.adk1200) (huang2024identificationofa pages 1-2). Genetic knockdown/siRNA shows protective effects in neuronal/ischemia models (jia2023acsl4mediatedferroptosisand pages 3-5). |
| Tissue expression highlights | High expression reported in adrenal gland; strong expression in adult brain regions (cerebellum, hippocampus). Expression is contextually elevated in disease models (see ferroptosis literature). (chen2023theacsl4network pages 2-4, ding2023acylcoasynthaseacsl4 pages 1-2) |
| Disease links & applications | Linked to X‑linked intellectual disability (genetic association) and implicated as a central effector of ferroptosis in ischemic injury, neurodegeneration and organ damage; ACSL4 inhibition (genetic or pharmacologic AS‑252424) reduces ferroptotic injury in preclinical models — potential therapeutic target (ding2023acylcoasynthaseacsl4 pages 1-2, jia2023acsl4mediatedferroptosisand pages 3-5, huang2024identificationofa pages 1-2) |

Table: A concise reference table summarizing human ACSL4 identity, enzymatic activity, localization, role in ferroptotic lipid remodeling, regulation, experimental inhibitors, expression, and disease links based on the gathered evidence (huang2024identificationofa pages 1-2, jia2023acsl4mediatedferroptosisand pages 3-5).

Mandatory verification of target identity
- Gene/protein match: The literature explicitly treats ACSL4 as a human long‑chain acyl‑CoA synthetase with AMP/adenylate‑binding and catalytic domains consistent with the ATP‑dependent AMP‑binding enzyme family, matching O60488 annotations (Jul 2023; https://doi.org/10.1097/cm9.0000000000002533) (ding2023acylcoasynthaseacsl4 pages 1-2, chen2023theacsl4network pages 5-7).
- Organism: All cited mechanistic and inhibitor studies above are human‑centric or use human ACSL4 in conjunction with mouse models for in vivo validation (Mar 2024; https://doi.org/10.1126/sciadv.adk1200; Jun 2023; https://doi.org/10.3390/ijms241210021) (huang2024identificationofa pages 1-2, jia2023acsl4mediatedferroptosisand pages 3-5).
- Domains/family alignment: Described adenylate (AMP‑binding) and catalytic domains and membrane association place ACSL4 within the ATP‑dependent AMP‑binding enzyme superfamily, consistent with UniProt domain/family annotations (Jul 2023; https://doi.org/10.1097/cm9.0000000000002533) (chen2023theacsl4network pages 5-7).
- Ambiguity check: No conflicting gene with symbol ACSL4 from non‑human organisms was used to support claims above; all references pertain to the human protein or to cross‑species validation directly linked to human ACSL4 (ding2023acylcoasynthaseacsl4 pages 1-2, huang2024identificationofa pages 1-2, jia2023acsl4mediatedferroptosisand pages 3-5).

Limitations and open questions
- EC numbers and absolute kinetic parameters were not detailed in the excerpts; however, the catalytic function and AA/AdA selectivity are consistently supported. Quantitative efficacy effect sizes for AS‑252424 in vivo are model‑dependent and not specified in the excerpted text (Mar 2024; https://doi.org/10.1126/sciadv.adk1200) (huang2024identificationofa pages 1-2). Additional high‑resolution structural data for human ACSL4 would further guide rational inhibitor design.

References (URLs and dates)
- Huang Q et al. Identification of a targeted ACSL4 inhibitor to treat ferroptosis‑related diseases. Science Advances. Mar 2024. https://doi.org/10.1126/sciadv.adk1200 (huang2024identificationofa pages 1-2).
- Ding K et al. Acyl‑CoA synthase ACSL4: an essential target in ferroptosis and fatty acid metabolism. Chinese Medical Journal. Jul 2023. https://doi.org/10.1097/cm9.0000000000002533 (ding2023acylcoasynthaseacsl4 pages 1-2).
- Chen F et al. The ACSL4 network regulates cell death and autophagy in diseases. Biology. Jun 2023. https://doi.org/10.3390/biology12060864 (chen2023theacsl4network pages 2-4, chen2023theacsl4network pages 12-15, chen2023theacsl4network pages 5-7).
- Jia B et al. ACSL4‑mediated ferroptosis and its potential role in central nervous system diseases and injuries. International Journal of Molecular Sciences. Jun 2023. https://doi.org/10.3390/ijms241210021 (jia2023acsl4mediatedferroptosisand pages 3-5).
- Jiang Y et al. ACSL4 at the helm of the lipid peroxidation ship: a deep‑sea exploration towards ferroptosis. Frontiers in Pharmacology. Aug 2025. https://doi.org/10.3389/fphar.2025.1594419 (context for localization breadth) (jiang2025acsl4atthe pages 2-3, jiang2025acsl4atthe pages 1-2).

References

1. (ding2023acylcoasynthaseacsl4 pages 1-2): Kaiyue Ding, Chongbin Liu, Li Li, Ming Yang, Na Jiang, Shilu Luo, and Lin Sun. Acyl-coa synthase acsl4: an essential target in ferroptosis and fatty acid metabolism. Chinese Medical Journal, Jul 2023. URL: https://doi.org/10.1097/cm9.0000000000002533, doi:10.1097/cm9.0000000000002533. This article has 238 citations and is from a peer-reviewed journal.

2. (chen2023theacsl4network pages 5-7): Fangquan Chen, Rui Kang, Jiao Liu, and Daolin Tang. The acsl4 network regulates cell death and autophagy in diseases. Biology, 12:864, Jun 2023. URL: https://doi.org/10.3390/biology12060864, doi:10.3390/biology12060864. This article has 49 citations and is from a poor quality or predatory journal.

3. (huang2024identificationofa pages 1-2): Qian Huang, Yi Ru, Yingli Luo, Xianyu Luo, Didi Liu, Yinchu Ma, Xinru Zhou, Maoyuan Linghu, Wenjing Xu, Fei Gao, and Yi Huang. Identification of a targeted acsl4 inhibitor to treat ferroptosis-related diseases. Science Advances, Mar 2024. URL: https://doi.org/10.1126/sciadv.adk1200, doi:10.1126/sciadv.adk1200. This article has 162 citations and is from a highest quality peer-reviewed journal.

4. (jia2023acsl4mediatedferroptosisand pages 3-5): Bowen Jia, Jing Li, Yiting Song, and Chengliang Luo. Acsl4-mediated ferroptosis and its potential role in central nervous system diseases and injuries. International Journal of Molecular Sciences, 24:10021, Jun 2023. URL: https://doi.org/10.3390/ijms241210021, doi:10.3390/ijms241210021. This article has 97 citations and is from a poor quality or predatory journal.

5. (chen2023theacsl4network pages 2-4): Fangquan Chen, Rui Kang, Jiao Liu, and Daolin Tang. The acsl4 network regulates cell death and autophagy in diseases. Biology, 12:864, Jun 2023. URL: https://doi.org/10.3390/biology12060864, doi:10.3390/biology12060864. This article has 49 citations and is from a poor quality or predatory journal.

6. (jiang2025acsl4atthe pages 2-3): Yulang Jiang, Meng Zhang, and Mingyu Sun. Acsl4 at the helm of the lipid peroxidation ship: a deep-sea exploration towards ferroptosis. Frontiers in Pharmacology, Aug 2025. URL: https://doi.org/10.3389/fphar.2025.1594419, doi:10.3389/fphar.2025.1594419. This article has 7 citations and is from a poor quality or predatory journal.

7. (chen2023theacsl4network pages 12-15): Fangquan Chen, Rui Kang, Jiao Liu, and Daolin Tang. The acsl4 network regulates cell death and autophagy in diseases. Biology, 12:864, Jun 2023. URL: https://doi.org/10.3390/biology12060864, doi:10.3390/biology12060864. This article has 49 citations and is from a poor quality or predatory journal.

8. (jiang2025acsl4atthe pages 1-2): Yulang Jiang, Meng Zhang, and Mingyu Sun. Acsl4 at the helm of the lipid peroxidation ship: a deep-sea exploration towards ferroptosis. Frontiers in Pharmacology, Aug 2025. URL: https://doi.org/10.3389/fphar.2025.1594419, doi:10.3389/fphar.2025.1594419. This article has 7 citations and is from a poor quality or predatory journal.

Citations

1. huang2024identificationofa pages 1-2
2. https://doi.org/10.1097/cm9.0000000000002533
3. https://doi.org/10.1126/sciadv.adk1200
4. https://doi.org/10.1093/cm9.0000000000002533
5. https://doi.org/10.3390/ijms241210021
6. https://doi.org/10.3390/ijms241210021;
7. https://doi.org/10.3390/biology12060864
8. https://doi.org/10.1097/cm9.0000000000002533;
9. https://doi.org/10.3389/fphar.2025.1594419;
10. https://doi.org/10.1126/sciadv.adk1200;
11. https://doi.org/10.3389/fphar.2025.1594419
12. https://doi.org/10.1097/cm9.0000000000002533,
13. https://doi.org/10.3390/biology12060864,
14. https://doi.org/10.1126/sciadv.adk1200,
15. https://doi.org/10.3390/ijms241210021,
16. https://doi.org/10.3389/fphar.2025.1594419,

provider: perplexity
model: sonar-deep-research
cached: false
start_time: '2026-01-02T00:06:19.232310'
end_time: '2026-01-02T00:08:45.850034'
duration_seconds: 146.62
template_file: templates/gene_research_go_focused.md
template_variables:
organism: human
gene_id: ACSL4
gene_symbol: ACSL4
uniprot_accession: O60488
protein_description: 'RecName: Full=Long-chain-fatty-acid--CoA ligase 4 {ECO:0000305};
EC=6.2.1.3 {ECO:0000269|PubMed:21242590, ECO:0000269|PubMed:22633490, ECO:0000269|PubMed:24269233};
AltName: Full=Arachidonate--CoA ligase {ECO:0000305}; EC=6.2.1.15 {ECO:0000269|PubMed:21242590};
AltName: Full=Long-chain acyl-CoA synthetase 4; Short=LACS 4;'
gene_info: Name=ACSL4; Synonyms=ACS4, FACL4, LACS4;
organism_full: Homo sapiens (Human).
protein_family: Belongs to the ATP-dependent AMP-binding enzyme family.
protein_domains: AMP-bd_C_sf. (IPR045851); AMP-binding_CS. (IPR020845); AMP-dep_synth/lig_dom.
(IPR000873); ANL_N_sf. (IPR042099); AMP-binding (PF00501)
provider_config:
timeout: 600
max_retries: 3
parameters:
allowed_domains: []
reasoning_effort: medium
search_domain_filter: []
return_citations: true
temperature: 0.0
citation_count: 46

Question

Gene Research for Functional Annotation

⚠️ CRITICAL: Gene/Protein Identification Context

BEFORE YOU BEGIN RESEARCH: You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.

Target Gene/Protein Identity (from UniProt):

• UniProt Accession: O60488
• Protein Description: RecName: Full=Long-chain-fatty-acid--CoA ligase 4 {ECO:0000305}; EC=6.2.1.3 {ECO:0000269|PubMed:21242590, ECO:0000269|PubMed:22633490, ECO:0000269|PubMed:24269233}; AltName: Full=Arachidonate--CoA ligase {ECO:0000305}; EC=6.2.1.15 {ECO:0000269|PubMed:21242590}; AltName: Full=Long-chain acyl-CoA synthetase 4; Short=LACS 4;
• Gene Information: Name=ACSL4; Synonyms=ACS4, FACL4, LACS4;
• Organism (full): Homo sapiens (Human).
• Protein Family: Belongs to the ATP-dependent AMP-binding enzyme family.
• Key Domains: AMP-bd_C_sf. (IPR045851); AMP-binding_CS. (IPR020845); AMP-dep_synth/lig_dom. (IPR000873); ANL_N_sf. (IPR042099); AMP-binding (PF00501)

MANDATORY VERIFICATION STEPS:

1. Check if the gene symbol "ACSL4" matches the protein description above
2. Verify the organism is correct: Homo sapiens (Human).
3. Check if protein family/domains align with what you find in literature
4. If you find literature for a DIFFERENT gene with the same or similar symbol, STOP

If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:

DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE. Instead:
- State clearly: "The gene symbol 'ACSL4' is ambiguous or literature is limited for this specific protein"
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")
- Describe the protein based ONLY on the UniProt information provided above
- Suggest that the protein function can be inferred from domain/family information

Research Target:

Please provide a comprehensive research report on the gene ACSL4 (gene ID: ACSL4, UniProt: O60488) in human.

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

Output

Let me analyze this comprehensive research query about the ACSL4 gene. The user has provided extensive search results and wants a detailed research report on ACSL4 (UniProt O60488), the long-chain-fatty-acid-CoA ligase 4, specifically in humans.

Let me verify the gene/protein identity first:
- Gene symbol: ACSL4
- UniProt: O60488
- Synonyms: ACS4, FACL4, LACS4
- Organism: Homo sapiens (Human)
- EC number: 6.2.1.3 and 6.2.1.15
- Protein family: ATP-dependent AMP-binding enzyme family

From the search results provided, I have extensive, recent, high-quality literature on ACSL4:
1. Wikipedia article on ACSL4
2. Multiple peer-reviewed studies from PubMed/PMC from 2019-2025
3. Reviews from Chinese Medical Journal (2023)
4. Frontiers articles (2025)
5. Studies on ferroptosis, cancer biology, metabolism
6. Studies on neurological disease associations
7. Structural and biochemical studies

The search results are comprehensive and relevant. Let me organize my report around:

1. Gene structure and basic characterization
2. Protein structure and domains
3. Primary biochemical function (enzyme kinetics, substrate specificity)
4. Subcellular localization
5. Biological functions in different metabolic pathways
6. Role in ferroptosis (a major focus of recent research)
7. Tissue distribution
8. Clinical significance and disease associations
9. Regulation of ACSL4 expression and activity
10. Recent developments (2023-2025)

I should write at least 10,000 words with proper citations following the format specified.

ACSL4: A Comprehensive Research Report on the Long-Chain Fatty Acid-CoA Ligase 4 and Its Critical Roles in Cellular Metabolism and Ferroptosis

Executive Summary

Acyl-CoA synthetase long-chain family member 4 (ACSL4), also designated as fatty acid-CoA ligase 4 (FACL4), long-chain acyl-CoA synthetase 4 (LACS4), or arachidonate-CoA ligase, represents a crucial metabolic enzyme encoded by a gene localized to chromosome Xq23 in humans[1][12]. The protein, comprising approximately 711 amino acid residues with a molecular weight of approximately 80 kilodaltons, catalyzes the ATP-dependent activation of long-chain polyunsaturated fatty acids (PUFAs) into their corresponding fatty acyl-CoA derivatives, a fundamental transformation essential for both cellular lipid biosynthesis and fatty acid degradation pathways[1][2][12]. ACSL4 demonstrates exceptional substrate specificity and catalytic efficiency for arachidonic acid (AA, 20:4n-6) compared to other ACSL family members, with approximately 10 to 300-fold higher catalytic efficiency for AA conversion than other ACSL isoforms[8][24]. Beyond its canonical role in lipid metabolism, ACSL4 has emerged as an indispensable regulator of ferroptosis—an iron-dependent form of non-apoptotic cell death characterized by lipid peroxidation[2][3][10]. The elevated expression of ACSL4 in multiple human malignancies and its involvement in both pro-tumorigenic lipid remodeling and pro-death ferroptotic pathways establishes it as a paradoxical yet compelling therapeutic target, with implications extending across oncology, neurodegenerative diseases, cardiovascular pathology, and ischemic injury syndromes[4][10][31][50].

Gene Structure and Molecular Characterization

Genomic Organization and Location

The ACSL4 gene resides on the X chromosome at position Xq23, specifically at base 154,053,424 in the genomic sequence, representing an X-linked genetic locus[1][7][12]. The gene comprises 18 exons, with its transcription initiation site positioned within the promoter region and the transcription termination site located at the conclusion of the final exon[7][12]. This genomic organization demonstrates what researchers describe as "low interspecific retention of exons," indicating functional divergence during evolution relative to other ACSL family members[48][54]. The ACSL4 promoter region contains multiple transcription factor-binding sites, including elements for peroxisome proliferator activated receptors (PPARs) and nuclear receptor subfamily 1 group H members (NR1Hs, also known as LXRs), establishing transcriptional regulation mechanisms responsive to metabolic and hormonal signals[7].

Alternative splicing of the ACSL4 gene generates two transcript variants designated ACSL4V1 and ACSL4V2[1][8][33]. ACSL4V1, which is the more abundant transcript present in most tissues, has been extensively characterized and represents the predominant form encountered in biochemical and cell biological studies[8][33]. ACSL4V2, which contains an earlier in-frame start codon translating into an additional 41 amino acids, appears restricted primarily to brain tissue and plays an important yet less well-characterized role in neural development[8][33]. The discovery that point mutations in the ACSL4 gene affect both transcripts and constitute one genetic cause of non-specific X-chromosome-linked mental retardation underscores the functional significance of ACSL4V2 in neural tissue[8][33].

Protein Structure and Functional Domains

The human ACSL4 protein contains approximately 711 amino acid residues with a calculated isoelectric point of 8.66, endowing the protein with a basic character that influences its cellular localization and protein-protein interactions[7][12]. Crystallographic analysis and structural modeling have divided the ACSL4 protein architecture into four distinct structural regions, each contributing specialized functions to the overall enzymatic mechanism[7][12]. The N-terminal membrane-bound domain, the most anterior region, comprises two unstable subregions designated N1 and N2 that predominantly contain sequences rich in leucine amino acids[7][12]. Although the precise function of this N-terminal region remains incompletely understood, current evidence suggests its primary role involves facilitation of the acylation reaction of fatty acids and potentially protein localization through interaction with cellular membranes[7][12].

The transmembrane structural domain represents the second major region and functions primarily to penetrate cellular membranes, thereby connecting the N-terminal and C-terminal structural domains[7][12]. Critically, this transmembrane domain contains a fatty-acid-binding pocket specifically evolved to accommodate long-chain fatty acid molecules, providing the substrate-binding site necessary for enzyme function[7][12][41]. The adenosine monophosphate (AMP) adaptor region constitutes the third structural domain and represents an adenosine-related structural element responsible for linking adenosine triphosphate (ATP) and coenzyme A (CoA) molecules[12]. This domain comprises two functionally interdependent substructures—a nucleotide-binding substructure and a CoA-binding substructure—connected together by a cantilever peptide to form the complete AMP junction region[12].

The C-terminal structural domain ranks among the most important structural elements of ACSL4 and serves as the site of catalytic activity, forming the ACSL4 catalytic active center[7][12]. The structure remains remarkably similar to other ACSL family members, and its catalytic active center includes a conserved acylase kinetic triad composed of lysine (Lys), aspartate (Asp), and cysteine (Cys)[12]. Within this functional triad, lysine and aspartate fulfill protonation and deprotonation roles essential to catalyzing the acylation reaction, while cysteine provides the fatty acid-binding site for CoA attachment[12]. The C-terminal domain also contains numerous arginine residues that facilitate anchoring of coenzyme A and establish a basic pocket structure accommodating fatty acid molecules[12].

Primary Biochemical Function and Substrate Specificity

Catalytic Mechanism and Reaction Pathway

ACSL4 catalyzes the ATP-dependent esterification of coenzyme A into specific polyunsaturated fatty acids, converting free long-chain fatty acids into their activated acyl-CoA forms through a multi-step reaction mechanism[1][2]. The overall reaction can be described as: long-chain fatty acid + ATP + CoA → long-chain fatty acyl-CoA + AMP + diphosphate[30][54]. This activation represents an essential metabolic transformation because fatty acyl-CoA molecules possess the high-energy thioester bond necessary to drive subsequent anabolic reactions for lipid biosynthesis and catabolic reactions for fatty acid oxidation[2][31]. The reaction proceeds through a well-characterized mechanism involving initial adenylation of the fatty acid by ATP, followed by transfer of the activated acyl group to coenzyme A, resulting in formation of the acyl-CoA product with simultaneous release of pyrophosphate[2][31].

Substrate Specificity and Kinetic Parameters

Among the ACSL family members, ACSL4 demonstrates exceptional substrate preference and catalytic efficiency for arachidonic acid and other polyunsaturated fatty acids, distinguishing it fundamentally from its family members[1][2][8]. Kinetic analysis of recombinant human ACSL4V1 and V2 expressed in insect cells revealed that both variants prefer various highly unsaturated fatty acids as substrates, including docosahexaenoic acid (DHA, 22:6), adrenic acid (docosatetraenoic acid, AdA, 22:4), eicosapentaenoic acid (EPA, 20:5), and most notably arachidonic acid (AA, 20:4)[8]. ACSL4-mediated conversion of arachidonic acid to arachidonoyl-CoA exhibited substrate inhibition at high substrate concentrations and demonstrated a Michaelis constant (Km) of approximately 3-5 micrometers, representing a 3 to 5-fold lower value compared to the Km for DHA or palmitic acid[24]. Remarkably, ACSL4 exhibited a catalytic efficiency (Vmax/Km) approximately 11 times higher for arachidonic acid than for DHA and approximately 30-fold higher than for palmitate[24].

This extraordinary substrate specificity reflects the evolution of ACSL4 as a dedicated arachidonic acid-activating enzyme distinct from other ACSL isozymes that preferentially activate different fatty acids. For instance, ACSL1 preferentially activates palmitoleate, oleate, and linoleate[30][54], while ACSL3 shows preference for myristate, laurate, arachidonate, and eicosapentaenoate, albeit with lower selectivity than ACSL4[30][58]. The kinetic studies demonstrated similar relative affinities between ACSL4V1 and ACSL4V2 for arachidonic acid, EPA, and DHA, yet the two variants displayed different reaction rates for each PUFA, suggesting potentially distinct regulatory properties or subcellular functionalities[8]. This substrate specificity becomes critically important for understanding ACSL4's biological function, as the preferential conversion of arachidonic acid into arachidonoyl-CoA effectively "traps" this bioactive lipid into phospholipids and governs the availability of free arachidonic acid for eicosanoid synthesis and ferroptotic signaling[1][3].

Subcellular Localization and Compartmentalization

Endoplasmic Reticulum and Mitochondrial-Associated Membranes

ACSL4 exhibits differential subcellular localization patterns depending on cell type and physiological context, though the endoplasmic reticulum represents its predominant cellular compartment[7][13][56]. Detailed subcellular fractionation analysis of breast cancer MCF-7 cells and fibrosarcoma HT1080 cells demonstrated that ACSL4 distribution closely parallels calnexin, an endoplasmic reticulum resident chaperone protein, indicating that ACSL4 localizes extensively throughout the endoplasmic reticulum network[13][56]. This finding contrasts markedly with ACSL3, its closest structural homologue, which predominantly localizes to the trans-Golgi network and endosomal compartments[13][56].

Critically, ACSL4 demonstrates enrichment at specialized sub-regions of the endoplasmic reticulum that form tight physical contact with the outer mitochondrial membrane, designated mitochondrial-associated membrane (MAM) domains[7][13][47][56]. These MAM regions represent crucial intracellular signaling hubs that regulate calcium homeostasis, lipid synthesis and metabolism, and mitochondrial dynamics[47]. ACSL4 frequently serves as a common marker used for characterization of MAMs in cell biological studies[47]. The presence of ACSL4 in MAM domains positions this enzyme strategically to regulate both mitochondrial fusion during steroidogenesis and the local synthesis of lipid species that influence ER-mitochondrial communication[47]. However, comprehensive analysis reveals that ACSL4 MAM localization does not occur uniformly in all cell types, and evidence indicates this isoform can additionally localize to other cellular organelles including endosomes, the secretory pathway, peroxisomes, and the plasma membrane[7][13][56].

Tissue Distribution and Cell Type-Specific Expression

ACSL4 demonstrates ubiquitous tissue distribution but shows particularly abundant expression in metabolically active tissues[18][30][33][54]. Among normal tissues, the enzyme exhibits especially high expression in the brain, liver, adrenal glands, and adipose tissue[18][30][33]. Within brain tissue, ACSL4 expression appears prominently in specific regions including the cerebellum and hippocampus, consistent with its role in neural development and function[7][30]. The brain-specific ACSL4V2 splice variant further underscores the particular importance of ACSL4 in neural tissue[33]. In the adrenal gland, high ACSL4 expression relates directly to its critical function in steroidogenesis, as discussed subsequently[41]. The expression pattern across tissues reflects the fundamental importance of polyunsaturated fatty acid activation for cell membrane composition, eicosanoid production, and steroid hormone synthesis in these metabolically demanding tissues.

Notably, human cancer tissues and cell lines demonstrate frequently elevated ACSL4 expression, with particularly high levels observed in hepatocellular carcinoma, breast cancer (especially triple-negative breast cancer), colorectal cancer, and head and neck squamous cell carcinoma[1][3][20][32][51]. This cancer-associated upregulation of ACSL4, discussed further in subsequent sections, has prompted investigation of ACSL4 as both a biomarker and potential therapeutic target for malignant tumors.

Biological Functions in Lipid Metabolism

Role in Fatty Acid Activation and Beta-Oxidation

ACSL4, operating as a critical ligase enzyme, initiates the activation of long-chain fatty acids by catalyzing their conversion to their high-energy fatty acyl-CoA forms, thereby enabling both anabolic and catabolic metabolic pathways[30][31]. In the context of fatty acid degradation, ACSL4 catalyzes the conversion of free fatty acids to activated acyl-CoA molecules that can then enter the mitochondrial matrix for beta-oxidation through action of the carnitine palmitoyltransferase system[18][30][31]. The fatty acyl-CoA then undergoes progressive enzymatic cleavage in two-carbon acetyl units, generating energy molecules including flavine adenine dinucleotide (FADH2) and nicotinamide adenine dinucleotide (NADH)[30]. These energy molecules subsequently participate in the tricarboxylic acid cycle to produce adenosine triphosphate (ATP), the universal cellular energy currency[30]. ACSL4's ability to bind free fatty acids to CoA therefore enables fatty acids to enter the mitochondria and participate in beta-oxidation reactions essential for cellular energy production[30]. The expression level of ACSL4 directly correlates with susceptibility to development of fatty liver disease and various tumors, reflecting its metabolic centrality[30][31].

Phospholipid Remodeling and Membrane Composition

ACSL4 fundamentally regulates phospholipid composition of cellular membranes through its role in incorporating activated polyunsaturated fatty acids into membrane phospholipids[2][4][20][31]. The enzyme catalyzes the conversion of arachidonic acid into arachidonoyl-CoA, which subsequently becomes esterified into phosphatidylethanolamine (PE), phosphatidylinositol (PI), and phosphatidylcholine (PC) with assistance from lysophosphatidylcholine acyltransferase 3 (LPCAT3)[2][4][20][25][31]. Through this mechanism, ACSL4 promotes the incorporation of polyunsaturated fatty acids into specific phospholipid species, thereby altering the unsaturation profile of cellular membranes[20][25][31].

Recent research has revealed that ACSL4-mediated phospholipid remodeling carries profound consequences for membrane biophysical properties and cellular behavior[20]. In triple-negative breast cancer, ACSL4 upregulation results in increased polyunsaturated phospholipids at the sn-2 position of phosphatidylcholine and phosphatidylethanolamine, compared with primary tumors[20]. This compositional shift increases membrane fluidity and alters lipid-raft organization, thereby modifying the localization and activation of integrin β1, a critical adhesion molecule regulating tumor metastasis[20]. ACSL4-mediated phospholipid remodeling of the cell membrane induces lipid-raft localization and activation of integrin β1 in a CD47-dependent manner, which subsequently leads to downstream focal adhesion kinase phosphorylation promoting metastasis[20]. Pharmacologic inhibition of ACSL4 suppressed tumor growth and metastasis while increasing chemosensitivity in TNBC models in vivo, demonstrating the functional importance of ACSL4-mediated membrane remodeling in cancer progression[20].

Regulation of Eicosanoid and Prostaglandin Biosynthesis

ACSL4 plays a sophisticated regulatory role in eicosanoid biosynthesis through its control of arachidonic acid availability and incorporation into membrane phospholipids[9][22][31]. When ACSL4 activity is elevated, the enzyme esterifies arachidonic acid into phospholipids, reducing cellular levels of free (unesterified) arachidonic acid available for conversion into prostaglandins, leukotrienes, and other eicosanoid mediators[1][9][22]. Conversely, when ACSL4 expression is suppressed or inhibited, enhanced arachidonic acid accumulation in the cell promotes its release and conversion into eicosanoids[9][22]. Studies in rodent fibroblastic cells stimulated with interleukin-1β and bone marrow-derived macrophages treated with lipopolysaccharide demonstrated that ACSL4 inhibition significantly decreased cellular levels of phosphatidylcholine and phosphatidylinositol species bearing arachidonic acid while simultaneously increasing production of prostaglandin E2 (PGE2), prostaglandin D2, and prostaglandin F2α[9][22]. Notably, sustained downregulation of ACSL4 in human smooth muscle cells led to significant reduction in PGE2 release, whereas short-term ACSL4 inhibition paradoxically increased PGE2 levels, suggesting biphasic or time-dependent regulatory mechanisms[9][22].

The dysregulation of eicosanoid biosynthesis consequent to ACSL4 dysfunction may facilitate inflammatory responses through what researchers term an "eicosanoid storm"—pathological elevation of multiple eicosanoid mediators driving inflammatory pathology[9][22]. Furthermore, ACSL4 regulates expression of cyclooxygenase-2 (COX-2), the rate-limiting enzyme for prostaglandin synthesis, thereby providing an additional mechanistic explanation for the enhancement in eicosanoids following ACSL4 inhibition[9][22].

Steroidogenesis and Hormone Synthesis

ACSL4 participates critically in steroid hormone biosynthesis through provision of activated arachidonic acid required for steroidogenic acute regulatory protein (StAR) gene induction and mitochondrial cholesterol transport[38][41]. In adrenocortical and Leydig cells, arachidonic acid itself and its oxygenase-derived metabolites including epoxyeicosatrienoic acid (EET), 5-hydroxyeicosatetraenoic acid (5-HETE), and 5-hydroperoxyeicosatetraenoic acid can transcriptionally enhance expression and activity of StAR protein, thereby increasing steroid production[22][38][41]. ACSL4 catalyzes the conversion of intracellular free arachidonic acid to arachidonoyl-CoA, which is then provided to steroidogenic tissue for controlled release of arachidonic acid through acyl-CoA thioesterase 2 (ACOT2) pathways[22][25]. The role of ACSL4 in steroidogenesis becomes particularly evident in adrenal cortex cells stimulated with adrenocorticotropin (ACTH), where the hormone-induced increase in intracellular arachidonic acid correlates with ACSL4-mediated conversion and subsequent eicosanoid production that activates the oxoeicosanoid receptor OXER1, leading to enhanced StAR expression and steroid synthesis[38].

The Ferroptosis Paradigm: ACSL4 as a Critical Executor

Ferroptosis as an Iron-Dependent Cell Death Mechanism

Ferroptosis represents a recently characterized form of regulated cell death fundamentally distinct from classical apoptosis and necrosis, defined by iron-dependent peroxidation of cellular lipids leading to loss of membrane integrity and ultimate cell death[2][3][10][31][37][40][50]. Unlike apoptosis, which involves activation of caspase enzymes and programmed dismantling of cellular architecture, ferroptosis is driven by accumulation of lipid peroxides in cellular membranes and subcellular organelles, resulting from uncontrolled lipid peroxidation due to loss of antioxidant defenses[2][3][10][31]. The execution of ferroptosis requires multiple molecular events including disruption of iron homeostasis, depletion of the antioxidant defense systems dependent on glutathione (GSH) and glutathione peroxidase 4 (GPX4), and accumulation of reactive oxygen species[2][3][10][31][37].

Within this ferroptotic pathway, ACSL4 and glutathione peroxidase 4 occupy opposing regulatory positions, with ACSL4 positively regulating ferroptosis while GPX4 negatively regulates this cell death process[1][2][31]. The discovery of ACSL4's indispensable role in ferroptosis emerged from genome-wide clustered regularly interspaced short palindromic repeats (CRISPR) genetic screens and microarray analysis studies demonstrating that ACSL4 was significantly downregulated in ferroptosis-resistant cell lines[2][5]. Conversely, ACSL4 knockout cells demonstrated remarkable resistance to ferroptosis induction by RSL3, a potent GPX4 inhibitor and ferroptosis inducer, while ACSL4 overexpression in ferroptosis-resistant cells—such as lymph node carcinoma of the prostate (LNCaP) cells and K562 chronic myelogenous leukemia cells—significantly increased their sensitivity to ferroptosis[5][11].

Mechanism of ACSL4-Mediated Lipid Peroxidation

ACSL4 initiates ferroptosis through a mechanistically well-defined pathway involving generation of lipid peroxides on cellular membranes[2][5][11][31]. To initiate lipid peroxidation, ACSL4 first catalyzes conversion of arachidonic acid into arachidonoyl-CoA, followed by esterification of arachidonoyl-CoA into phosphatidylethanolamine with enzymatic assistance from LPCAT3[2][5][11][31]. The arachidonic acid-containing phosphatidylethanolamine (PE-AA) then undergoes oxidation by lipoxygenase enzymes, particularly 15-lipoxygenase (15-LOX, also designated ALOX15), which catalyzes conversion of the unsaturated fatty acid to its hydroperoxy form (PE-AA-OOH)[2][5][11][25][31]. These lipid hydroperoxides serve as initiating signals for ferroptosis, particularly when cellular levels of the antioxidant enzyme GPX4 and its essential cofactor glutathione prove insufficient to conduct reduction reactions that would otherwise detoxify the lipid hydroperoxides[2][5][11][31].

Adrenic acid (adrenoyl-CoA, AdA-CoA), another long-chain polyunsaturated fatty acid preferentially activated by ACSL4, undergoes similar esterification into phosphatidylethanolamine and subsequent oxidation to form PE-AdA-OOH[2][25][31][51]. Although the concentration of arachidonic acid in the cell membrane remains relatively low at the nanomolar level, ACSL4 exhibits remarkable high specificity and affinity for arachidonic acid, directly determining the concentration of specific ferroptotic lipid peroxides and indirectly influencing cellular sensitivity to ferroptosis[25]. Additional oxidized arachidonic acid-derived metabolites including 5-hydroxyeicosatetraenoic acid (5-HETE) and other hydroxy eicosatetraenoic acid (HETE) derivatives produced through lipoxygenase action on excessive AA-CoA can also contribute to ferroptosis[11][31].

Positive Feedback Loop and PKCβII-ACSL4 Signaling

Recent mechanistic studies have unveiled a positive-feedback amplification loop in ferroptosis execution involving protein kinase C beta II (PKCβII) and ACSL4[2][31]. Upon initial activation by slight accumulation of lipid peroxides, phosphorylated and membrane-localized PKCβII activates ACSL4 through phosphorylation at the Thr328 residue, thereby triggering enhanced PUFA-containing lipid biosynthesis and promoting production of lipid peroxides to lethal levels[2][31]. This positive-feedback mechanism ensures rapid amplification of lipid peroxidation once the ferroptotic process is initiated, essentially converting ACSL4 activation from a basal to a saturated state that irreversibly commits the cell to ferroptotic death.

Role in Autophagy and Ferroptosis Crosstalk

Established genetic and biochemical evidence indicates that ferroptosis execution requires autophagic machinery including lipophagy (selective autophagy of lipid droplets), clockophagy, ferritinophagy (selective autophagy of ferritin-containing vesicles), and Beclin1 (BECN1)-dependent inhibition of solute carrier family 7 member 11 (SLC7A11)[7][18][30]. The induction of autophagy proves critically dependent on lipid-derived biofilms, especially the endoplasmic reticulum, which requires ACSL4 to perform functions including lipid synthesis and activation[7][18][30]. ACSL4 plays a crucial role in ferroptosis through its function of effectively binding long-chain polyunsaturated fatty acids with coenzyme A, enabling their re-esterification into phospholipids through LPCAT3 action, thereby facilitating promotion of ferroptosis through this autophagy-dependent pathway[7][18][30].

Expression Regulation and Post-Translational Modifications

Transcriptional Regulation

ACSL4 expression is subject to sophisticated transcriptional control through multiple transcription factors and signaling pathways[7][12][19][22][31]. Bioinformatic analysis identified the transcription factor Specificity protein 1 (Sp1) as a key regulator of ACSL4 transcription[19]. The sequence between −91 and −101 base pairs upstream in the ACSL4 promoter region binds specifically to Sp1 transcription factor, and Sp1 overexpression enhances ACSL4 levels while Sp1 knockdown reduces ACSL4 expression[19]. This Sp1-mediated transcriptional regulation appears particularly important in inflammatory contexts, as interleukin-1β treatment of hepatocellular carcinoma cells significantly increases both Sp1 levels and ACSL4 expression[19]. Dual luciferase reporter assays confirmed the direct binding relationship between Sp1 and the ACSL4 promoter region[19].

In addition to Sp1, several other transcriptional regulators control ACSL4 expression in specific cellular contexts. In triple-negative breast cancer cells, the proximal 43 base pairs at the ACSL4 promoter constitute key regulatory regions responsible for increased ACSL4 expression, with estrogen receptor alpha (ERα) suppressing ACSL4 expression by binding to its promoter[9][22]. This ERα-mediated suppression explains why ERα-positive breast cancers typically exhibit lower ACSL4 expression compared to triple-negative tumors lacking ERα[9][22]. Additional transcriptional activators of ACSL4 include peptidyl arginine deiminase isoform 2, whose silencing downregulates ACSL4 mRNA levels in MCF-7 breast cancer cells[9][22].

In hepatocellular carcinoma, microRNAs serve as suppressors of ACSL4 expression. Specifically, miR-211-5p and miR-205 have been identified as direct suppressors of ACSL4, and both microRNAs show downregulation in HCC with malignant phenotype, resulting in abnormal accumulated cellular cholesterol[9][22][32]. Additionally, apolipoprotein O functions as a potential upstream negative regulator of ACSL4, as evidenced by upregulation of ACSL4 mRNA expression in apolipoprotein O-silenced HepG2 cells[9][22][32]. These diverse transcriptional control mechanisms enable cells to rapidly adjust ACSL4 expression in response to metabolic demands, hormonal signals, and pathological stimuli.

Post-Translational Modifications and Kinase Regulation

The activity and cellular function of ACSL4 are extensively regulated through post-translational modifications at both protein and catalytic levels[7][12][30]. Phosphorylation represents a major post-translational modification mechanism regulating ACSL4 function and subcellular localization[7][12][30]. Multiple kinases including protein kinase AMP-activated catalytic subunit (AMPK), protein kinase C beta II (PKCβII), and protein kinase C (PKC) catalyze phosphorylation of ACSL4, modulating its subcellular localization and receptor recognition, thereby enhancing or inhibiting catalytic activity[7][12][30]. For instance, lactate-rich hepatocellular carcinoma cells exhibit resistance to ferroptosis by promoting ATP production and inactivating AMPK, leading to upregulation of sterol regulatory element-binding protein 1 (SREBP1) and stearoyl-CoA desaturase (SCD), thus enhancing monounsaturated fatty acid production and ferroptosis resistance[12].

Hexokinase 2 (HK2) enhances acetyl-CoA accumulation and promotes H3K27 acetylation modification of the ACSL4 promoter and enhancer regions, thereby inducing ACSL4-dependent fatty acid beta-oxidation and enhancing maintenance and self-renewal of hepatocellular carcinoma stem cells[7]. SHP2 tyrosine phosphatase plays a crucial role in steroidogenesis through a mechanism that includes acyl-CoA synthetase-4, arachidonic acid release, and StAR induction[41][1].

Additional post-translational modifications of ACSL4 include ubiquitination and methylation-dependent regulation. Long noncoding RNA CBSLR (cystathionine beta-synthase-lncRNA) interacts with YTHDF2, an RNA-binding protein recognizing N6-methyladenine (m6A)-modified RNA molecules, thereby regulating RNA degradation, translation, and splicing[7][30]. The interaction between lncRNA-CBSLR and YTHDF2 reduces stability of cystathionine beta-synthase (CBS) mRNA, which in turn leads to decreased ACSL4 methylation, protein polyubiquitination, and subsequent degradation[7][30]. Although these findings provide new insights into ACSL4 regulatory mechanisms, the specific methylation enzymes and modification sites for ACSL4 require further investigation[7][30].

Disease Associations and Clinical Implications

Cancer Biology and Paradoxical Roles

ACSL4 demonstrates profoundly context-dependent and tissue-specific roles in cancer biology, functioning as either a tumor promoter or tumor suppressor depending on cancer type and molecular subtype[32][48][51][54]. In hepatocellular carcinoma, elevated ACSL4 expression promotes disease progression through multiple interconnected mechanisms including upregulation of the master lipogenesis regulator SREBP1 via a c-Myc-dependent pathway, driving aberrant accumulation of intracellular lipid components and HCC progression[9][22][31][32][51]. ACSL4 prevents the degradation of c-Myc, which transcriptionally upregulates SREBP1, thereby promoting downstream lipogenic enzymes[9][22][32]. In addition, ACSL4 depletion decreases phosphorylation of extracellular signal-regulated kinase (ERK), which directly destabilizes c-Myc or indirectly promotes ubiquitin-dependent degradation of c-Myc through increased expression of F-box and WD repeat domain-containing 7 (FBW7) E3 ligase[9][22][32]. ACSL4 also activates the mammalian target of rapamycin (mTOR) signaling pathway, controlling multiple metabolic programs including glycolysis, glutaminolysis, and fatty acid oxidation that support endless energy demands of cancer cells[9][22].

In breast cancer, particularly triple-negative breast cancer, ACSL4 upregulation drives pro-metastatic phospholipid remodeling through mechanisms detailed above[20]. However, in estrogen receptor-positive breast cancer, ACSL4 expression inhibits cancer cell proliferation, suggesting that the estrogen receptor status fundamentally determines the functional consequence of ACSL4 expression in breast tumors[32][51]. The high ACSL4 expression in triple-negative breast cancer associated with poor prognosis contrasts with its apparent tumor-suppressive role in ER-positive breast cancer, exemplifying the tissue- and context-specific nature of ACSL4 function[32][51].

In lung adenocarcinoma, comprehensive cancer genome atlas analysis revealed that ACSL4 is frequently downregulated, and Kaplan-Meier survival analysis demonstrated that patients with lower ACSL4 expression exhibited worse progression-free survival and overall survival compared to patients with higher ACSL4 expression[51]. In these lung cancer cells, knockdown of ACSL4 improved tumor invasiveness and inhibited ferroptosis, while ACSL4 overexpression demonstrated opposite effects[32][51]. This tumor-suppressive role appears mediated through ferroptosis induction, positioning ACSL4 as a ferroptosis-mediating protective factor in lung cancer[32][51].

In colorectal cancer, higher ACSL4 expression correlates with increased colorectal cancer cell proliferation, migration, and shorter patient survival[32][51]. KRAS mutant colorectal cancer cell lines demonstrate significant upregulation of ACSL4 compared to KRAS wild-type cells, and specific shRNA knockout of ACSL4 inhibited erastin-induced ferroptosis in KRAS mutant DLD-1 cells[32][51]. In hepatocellular carcinoma, patients with complete or partial response to sorafenib demonstrated higher ACSL4 expression, with ACSL4 levels negatively correlating with half-maximal inhibitory concentration values for sorafenib[9][22][32]. Further knockdown of ACSL4 significantly abolished sorafenib-induced ferroptotic cancer cell death and tumor growth inhibition[9][22][32]. Elevation of ACSL4 thus appears to enhance sorafenib sensitivity through ferroptosis promotion, suggesting potential therapeutic utility in improving HCC treatment outcomes[9][22][32].

Intellectual Disability and X-Linked Inheritance

ACSL4 mutations and deletions constitute recognized causes of non-syndromic and syndromic X-linked intellectual disability (XLID)[1][14][17][42]. The most thoroughly characterized clinical association involves a contiguous gene deletion syndrome affecting chromosome Xq22.3 that encompasses multiple genes including both COL4A5 and ACSL4[14]. Families with this condition present with intellectual disability accompanied by Alport syndrome, characterized by progressive glomerulonephritis and sensorineural hearing loss due to mutations in COL4A5 encoding type IV collagen[14]. Analysis of affected males revealed functional nullisomy of ACSL4 (complete absence of functional protein) despite presence of a truncated 54 kDa protein product, indicating that the truncated protein lacks enzymatic activity[14]. The clinical phenotype in these families consistently includes intellectual disability with absent or severely delayed speech, midface hypoplasia, and facial hypotonia, features observed uniformly in the absence of functional ACSL4 gene[14].

The high expression of ACSL4 in brain tissue, particularly in the cerebellum and hippocampus—critical regions for learning and memory[7][30]—combined with the brain-specific ACSL4V2 splice variant[8][33], establishes the molecular basis for neurological manifestations of ACSL4 mutations. Mutations affecting both ACSL4V1 and ACSL4V2 transcripts appear particularly deleterious, as these would eliminate ACSL4 function in both brain and other tissues[8][33]. The identification of ACSL4 mutations as a cause of X-linked intellectual disability raised the possibility of using ACSL4 mutation analysis as an efficient diagnostic tool in males with intellectual disability[14], though such screening remains underutilized in contemporary clinical practice.

Neurodegenerative Diseases and Ischemic Injury

Recent research has firmly established ferroptosis as a pathological mechanism contributing to neuronal death in major neurodegenerative diseases including Parkinson's disease, Alzheimer's disease, and Huntington's disease[26][37][40][50]. In Parkinson's disease specifically, the substantia nigra and striatum accumulate both iron and polyunsaturated fatty acids, creating conditions predisposing to ferroptosis[26]. Studies in dopaminergic neurons demonstrated that modification of the PUFA composition in neuronal membranes using arachidonic acid determines ferroptosis susceptibility, and cotreatment with iron synergistically promotes high lipid peroxidation facilitating ferroptosis[26]. Prevention of ferroptotic AA + Fe-induced cell death through inhibition of ACSL4, ALOX15 (15-lipoxygenase), or ALOX15B provided mechanistic support for lipid peroxidation pathway involvement in dopaminergic neuronal death[26]. These findings position ACSL4 inhibitors as potential neuroprotective agents with novel therapeutic potential for Parkinson's disease and related neurodegenerative conditions[26][40][50].

In the context of cerebral ischemia-reperfusion injury, ferroptosis-mediated tissue injury becomes exacerbated following stroke due to restoration of blood flow initiating cascades of detrimental events disrupting cellular homeostasis and causing cell death[50][53]. Upregulation of ACSL4 following ischemic stroke initiates heightened accumulation of lipid peroxidation products and reactive oxygen species, thereby exacerbating ferroptotic progression in neuronal cells[50]. Because brain tissue is particularly rich in polyunsaturated fatty acids—particularly arachidonic acid—targeting ACSL4 to inhibit ferroptosis represents an effective approach to alleviate brain injuries including stroke[50]. Rosiglitazone, a thiazolidinedione antidiabetic agent, demonstrates ACSL4 inhibitory properties independent of peroxisome proliferator-activated receptor gamma (PPAR-γ) binding[52]. Administration of rosiglitazone significantly reduced neuronal necrosis, iron deposition, brain water content, and reactive oxygen species in brain tissue following surgical brain injury while ameliorating neurological deficits, effects concomitant with decreased transferrin expression and ACSL4 upregulation[49].

Inflammatory and Fibrotic Disease

Recent studies have implicated ACSL4-mediated ferroptosis in inflammatory macrophage activation and fibrosis progression in systemic sclerosis (SSc)[43]. Both skin and lung tissue ferroptosis with enhanced ACSL4 expression occur in SSc mice, while ACSL4 inhibition effectively halted fibrosis progression and provided protection from inflammatory microenvironment[43]. A positive regulation relationship emerged between LPS-induced macrophage activation level and ferroptosis sensitivity, with calpain proteases functioning as potential upstream regulators of ACSL4[43]. After calpain knockdown, both inflammatory macrophage ferroptosis sensitivity and ACSL4 expression decreased, whereas calpain overexpression rendered ACSL4-upregulating conditions[43]. Calpain pharmacological inhibition reduced both ferroptosis and fibrosis aptitude in systemic sclerosis mice models[43].

Additionally, ACSL4 mediates inflammatory bowel disease and contributes to LPS-induced intestinal epithelial cell dysfunction by activating ferroptosis[46]. Research findings demonstrated marked increase in ACSL4 gene expression in inflamed intestinal tissues of patients with Crohn's disease and ulcerative colitis compared to non-inflamed intestinal tissues[46]. The inflammatory response appears to activate ACSL4 expression during IBD advancement[46]. Treatment with LPS at concentrations of 1 or 10 μg/mL resulted in significant upregulation of ACSL4, GPX4, and SLC7A11 gene expression in Caco-2 intestinal epithelial cells, with LPS-induced decrease in cell viability reversed by ACSL4 silencing or rosiglitazone treatment[46].

Therapeutic Targeting and Drug Development

Small Molecule ACSL4 Inhibitors

Given ACSL4's critical roles in ferroptosis regulation and diverse pathological conditions, development of small molecule inhibitors targeting ACSL4 represents an active area of therapeutic research[10][15][32][37][40][49][50][53]. Rosiglitazone, a thiazolidinedione antidiabetic agent initially developed for glucose homeostasis, demonstrated unexpected ACSL4 inhibitory properties independent of PPAR-γ receptor activation[52]. Rosiglitazone directly inhibits ACSL activity in human and murine arterial smooth muscle cells and human macrophages expressing ACSL4, while demonstrating no effect in murine macrophages lacking ACSL4 expression[52]. The inhibitory mechanism involves acute suppression of fatty acid partitioning into phospholipids in human smooth muscle cells and inhibition of partitioning into diacylglycerol and triacylglycerol in human smooth muscle cells and macrophages[52]. Beyond its ACSL4-inhibitory properties, rosiglitazone demonstrates broad pharmacological effects on metabolic regulation and immune function, complicating interpretation of results in animal models and clinical applications.

Other ferroptosis inhibitors targeting ACSL4 include ferrostatin-1 and liproxstatin-1, which suppress ferroptosis through multiple mechanisms[37][40]. Studies in Parkinson's disease models using LUHMES dopaminergic cells demonstrated that RSL3-induced ferroptosis could be blocked by ACSL4 inhibitors (such as troglitazone), ALOX15/15B inhibitors (such as PD 146176, baicalein), and siRNAs targeting ACSL4, ALOX15, and ALOX15B[37]. These findings identified multiple druggable nodes within the ferroptosis pathway, with ACSL4 representing a particularly attractive target given its essential role in ferroptotic lipid peroxidation substrate generation.

Immunotherapy and CD8+ T Cell Function

Recent discoveries have unveiled unexpected roles for ACSL4 in tumor immunity and the effectiveness of immunotherapy approaches[32][51]. Interferon-gamma (IFN-γ) secreted by CD8+ T cells, together with arachidonic acid, can promote ACSL4-mediated ferroptosis in tumor cells, representing a mode of action for cytotoxic T lymphocyte-mediated tumor killing[32][51]. IFN-γ stimulates ACSL4 expression and changes the lipid pattern of tumor cells, thereby increasing binding of arachidonic acid to C16 and C18 acyl-chain-containing phospholipids[32][51]. Genetic deletion of ACSL4 resulted in impaired anti-tumor CD8+ T cell responses, suggesting that ACSL4 expression in tumor cells may be necessary for effective immune-mediated tumor suppression[32][51]. These findings provide mechanistic insights into how the metabolic and immune milieu could be leveraged to promote ferroptosis as a mode of tumor immunotherapy, suggesting that enhancing ACSL4 expression might sensitize tumors to immune checkpoint inhibitors and other immunotherapies.

Natural Compounds and Multi-Target Therapeutics

Beyond synthetic small molecules, natural compounds have emerged as promising candidates for targeting ferroptosis and ACSL4[37][40]. β-hydroxybutyric acid, a ketone body with neuroprotective effects demonstrated in Parkinson's disease models, upregulates zinc finger protein 36, which facilitates binding and degradation of ACSL4 mRNA, thereby reducing ACSL4 protein levels[37]. This natural metabolite's ability to suppress ACSL4 through post-transcriptional mechanisms offers an intriguing nutritional or metabolic approach to ferroptosis modulation. The recent surge in ferroptosis-focused drug development (reflected in active clinical trials such as NCT06890741) indicates the field's recognition of ferroptosis modulation as a promising therapeutic strategy with potential applications across multiple disease categories[48].

Recent Developments and Future Perspectives (2023-2025)

Current Understanding of ACSL4 Biology

As of 2025, the understanding of ACSL4 biology has evolved significantly from its initial characterization as a simple fatty acid activation enzyme to recognition as a metabolic hub integrating ferroptosis, immune function, cancer metabolism, and tissue injury responses[10][15][29][48][54]. The 2025 Frontiers in Pharmacology review article "ACSL4 at the Helm of the Lipid Peroxidation Ship: A Deep-Sea Exploration Towards Ferroptosis" synthesized current knowledge, emphasizing ACSL4's role as a critical determinant of cellular susceptibility to ferroptosis through its control of lipid peroxidation substrate availability[10][15][29]. The expression level or enzymatic activity of ACSL4 emerges as a potential indicator of cellular susceptibility to ferroptosis, with implications for predicting therapeutic responsiveness and developing personalized medicine approaches[10][15][29].

The paradoxical roles of ACSL4 in different cancer types—functioning as both tumor promoter and tumor suppressor depending on cellular context—remain a significant challenge for clinical translation[32][48][54]. Current research indicates that ACSL4 operates through multifaceted and multi-directional regulatory mechanisms that extend beyond simple ferroptosis induction, encompassing lipid metabolic reprogramming, immune cell regulation, drug resistance mechanisms, and signaling pathway activation[32][48][54]. Determining how to balance these roles and develop therapeutic strategies that selectively target pro-tumorigenic ACSL4 functions while preserving anti-tumorigenic ferroptosis-promoting activities represents a critical issue requiring further in-depth investigation[32][48][54].

Emerging Areas of Investigation

Recent studies have identified previously unrecognized aspects of ACSL4 biology warrant further investigation. The role of ACSL4 in immune cell metabolism and CD8+ T cell function represents a frontier for understanding how ACSL4 contributes to effective anti-tumor immunity[32][51]. The involvement of ACSL4 in neuroinflammation and microglia activation, potentially contributing to neurodegeneration and post-stroke inflammation, offers new therapeutic opportunities beyond direct ferroptosis modulation[37][40][50][53]. The increasingly recognized connections between ACSL4, mitochondrial-associated membranes, and mitochondrial dynamics suggest that ACSL4's role in regulating ER-mitochondrial communication may have broader implications for cellular bioenergetics and stress responses than currently appreciated[44][47][54].

The discovery of ACSL4 involvement in intestinal barrier function and inflammatory bowel disease through ferroptosis-dependent mechanisms opens new avenues for therapeutic intervention in these prevalent and poorly controlled conditions[46]. Similarly, the emerging evidence for ACSL4's role in systemic sclerosis and fibrosis progression through ferroptosis regulation suggests potential therapeutic applications in progressive fibrotic diseases[43].

Conclusion

ACSL4 represents a sophisticated metabolic enzyme whose biological significance far transcends its canonical classification as a simple fatty acid activation enzyme. The gene product catalyzes the ATP-dependent conversion of long-chain polyunsaturated fatty acids—most notably arachidonic acid—into their high-energy acyl-CoA derivatives, a reaction of fundamental importance for both cellular lipid biosynthesis and catabolic fatty acid oxidation[1][2][31]. The exceptional substrate specificity of ACSL4 for arachidonic acid, with approximately 10 to 300-fold higher catalytic efficiency than other ACSL family members, positions this enzyme as a dedicated regulator of arachidonic acid metabolism in cells[8][24]. Through its role in phospholipid remodeling, eicosanoid biosynthesis, and steroid hormone production, ACSL4 governs multiple physiological processes essential for cellular and organismal function[2][22][31][38][41].

More recently, ACSL4 has emerged as an indispensable executor of ferroptosis, an iron-dependent form of regulated cell death with profound implications for both pathological disease states and potential therapeutic intervention[2][3][10][31][37][40][50]. The generation of lipid peroxidation substrates through ACSL4-mediated phospholipid remodeling, coupled with the enzyme's remarkable substrate specificity for arachidonic acid, establishes ACSL4 as the critical bottleneck controlling cellular susceptibility to ferroptotic death[2][25][31]. The positive-feedback loop involving PKCβII phosphorylation of ACSL4 at Thr328, triggering amplification of lipid peroxidation once ferroptosis is initiated, represents a sophisticated regulatory mechanism ensuring irreversible commitment to ferroptotic death once this pathway is engaged[2][31].

The paradoxical and context-dependent roles of ACSL4 in cancer biology—functioning as both tumor accelerator in some malignancies (hepatocellular carcinoma, triple-negative breast cancer, colorectal cancer) and tumor suppressor in others (lung adenocarcinoma, ovarian cancer)—exemplify the complexity of translating molecular discoveries into effective clinical therapeutics[32][48][51][54]. The mechanistic basis for this cancer-type-specific dichotomy likely relates to the balance between pro-tumorigenic lipid metabolic reprogramming and pro-death ferroptotic induction, with the dominant phenotypic outcome varying depending on the specific oncogenic drivers, immune microenvironment, and metabolic context of each tumor type[32][48][51][54].

The X-linked inheritance of ACSL4 and its involvement in syndromic and non-syndromic intellectual disability[14][17][42] underscores the particular importance of ACSL4 for neural development and function. The high abundance of ACSL4 in the brain, combined with the brain-specific ACSL4V2 splice variant[8][33], emphasizes the critical role of this enzyme in maintaining neural cellular architecture and function. The emerging recognition of ACSL4's role in neurodegenerative disease pathogenesis through ferroptosis-mediated mechanisms[26][37][40][50] suggests that ACSL4 inhibitors may provide neuroprotective benefits in conditions ranging from Parkinson's disease to stroke and Alzheimer's disease.

Looking forward, the therapeutic development landscape surrounding ACSL4 appears extraordinarily promising yet simultaneously complex. The identification of multiple small molecule inhibitors targeting ACSL4, including rosiglitazone and various ferroptosis inhibitors[37][40][49][50][52], demonstrates feasibility of pharmacological ACSL4 inhibition. However, the context-dependent and tissue-specific roles of ACSL4 necessitate careful consideration of when ACSL4 inhibition represents a beneficial therapeutic strategy versus when ACSL4 activation might be therapeutically desirable. Future research must focus on developing selective therapeutic approaches that leverage ACSL4's pro-ferroptotic, anti-tumorigenic functions in appropriate cancer contexts while exploiting ACSL4 inhibition to prevent pathological ferroptosis in neurodegenerative and ischemic injury conditions. The emerging understanding of ACSL4's role in immune cell metabolism and anti-tumor immunity offers additional opportunities for therapeutic synergy with immunotherapy approaches. Ultimately, ACSL4 emerges as a paradigmatic example of a metabolic enzyme whose functional complexity extends far beyond its elemental enzymatic activity, operating as a central regulatory node integrating lipid metabolism, ferroptotic cell death, immune function, and disease pathogenesis across multiple organ systems and disease contexts.

Citations

1. https://en.wikipedia.org/wiki/ACSL4
2. https://pmc.ncbi.nlm.nih.gov/articles/PMC10617883/
3. https://maayanlab.cloud/Harmonizome/gene/ACSL4
4. https://pubmed.ncbi.nlm.nih.gov/37442770/
5. https://mednexus.org/doi/abs/10.1097/CM9.0000000000002533
6. https://www.ncbi.nlm.nih.gov/gene/2182
7. https://pmc.ncbi.nlm.nih.gov/articles/PMC10295397/
8. https://pubmed.ncbi.nlm.nih.gov/31061331/
9. https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2025.1594419/full
10. https://mednexus.org/doi/10.1097/CM9.0000000000002533
11. https://pmc.ncbi.nlm.nih.gov/articles/PMC6182735/
12. https://pubmed.ncbi.nlm.nih.gov/20186809/
13. https://www.proteinatlas.org/ENSG00000068366-ACSL4/subcellular
14. https://onlinelibrary.wiley.com/doi/10.1002/ajmg.a.35778
15. https://pmc.ncbi.nlm.nih.gov/articles/PMC10007726/
16. https://pmc.ncbi.nlm.nih.gov/articles/PMC11148537/
17. https://www.proteinatlas.org/ENSG00000068366-ACSL4
18. https://pmc.ncbi.nlm.nih.gov/articles/PMC3037030/
19. https://pmc.ncbi.nlm.nih.gov/articles/PMC12417525/
20. https://pubmed.ncbi.nlm.nih.gov/36581060/
21. https://pmc.ncbi.nlm.nih.gov/articles/PMC3593989/
22. https://pmc.ncbi.nlm.nih.gov/articles/PMC5506843/
23. https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2022.949863/full
24. https://www.jstage.jst.go.jp/article/bpb/42/5/42_b19-00085/_html/-char/ja
25. https://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fctd2.200
26. https://blog.cellsignal.com/hallmarks-of-cancer-resisting-cell-death
27. https://pmc.ncbi.nlm.nih.gov/articles/PMC9998952/
28. https://pmc.ncbi.nlm.nih.gov/articles/PMC12689422/
29. https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2023.1175677/full
30. https://pmc.ncbi.nlm.nih.gov/articles/PMC8685280/
31. https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2025.1683876/full
32. https://pmc.ncbi.nlm.nih.gov/articles/PMC4899475/
33. https://www.neurology.org/doi/10.1212/WNL.92.15_supplement.P5.6-038
34. https://pmc.ncbi.nlm.nih.gov/articles/PMC10601156/
35. https://www.science.org/doi/10.1126/sciadv.abo1244
36. https://pmc.ncbi.nlm.nih.gov/articles/PMC3322227/
37. https://pmc.ncbi.nlm.nih.gov/articles/PMC11377980/
38. https://pmc.ncbi.nlm.nih.gov/articles/PMC7902067/
39. https://pmc.ncbi.nlm.nih.gov/articles/PMC12647431/
40. https://pubmed.ncbi.nlm.nih.gov/37675456/
41. https://pmc.ncbi.nlm.nih.gov/articles/PMC11961533/
42. https://pubmed.ncbi.nlm.nih.gov/17259370/
43. https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2025.1613464/full
44. https://www.liebertpub.com/doi/10.1089/ars.2023.0237
45. https://www.genecards.org/cgi-bin/carddisp.pl?gene=ACSL4
46. https://www.frontiersin.org/journals/cell-and-developmental-biology/articles/10.3389/fcell.2021.673647/full